Cholesterol-binding translocator protein TSPO regulates steatosis and bile acid synthesis in nonalcoholic fatty liver disease

Yuchang Li, Liting Chen, Lu Li, ..., Bangyan Stiles, Kinji Asahina, Vassilios Papadopoulos

vpapadop@usc.edu

Highlights

- TSPO expression levels correlate with the progression of NAFLD
- TSPO deficiency inhibits ACAT2 leading to FC accumulation
- Loss of TSPO in hepatocytes leads to FC accumulation that promotes simple steatosis
- Loss of TSPO attenuates liver fibrosis via downregulation of bile acid production

Li et al., iScience 24, 102457
May 21, 2021 © 2021 The Author(s).
https://doi.org/10.1016/j.isci.2021.102457
OPEN ACCESS
Cholesterol-binding translocator protein TSPO regulates steatosis and bile acid synthesis in nonalcoholic fatty liver disease

Yuchang Li, Liting Chen, Lu Li, Chantal Sottas, Stephanie K. Petrillo, Anthoula Lazaris, Peter Metrakos, Hangyu Wu, Yuji Ishida, Takeshi Saito, Lucy Golden-Mason, Hugo R. Rosen, Jeremy J. Wolff, Cristina I. Silvescu, Samuel Garza, Garrett Cheung, Tiffany Huang, Jinjiang Fan, Martine Culty, Bangyan Stiles, Kinji Asahina, and Vassilios Papadopoulos

SUMMARY
Translocator protein (TSPO, 18 kDa) levels increase in parallel with the evolution of simple steatosis (SS) to nonalcoholic steatohepatitis (NASH) in nonalcoholic fatty liver disease (NAFLD). However, TSPO function in SS and NASH is unknown. Loss of TSPO in hepatocytes in vitro downregulated acetyl-CoA acetyltransferase 2 and increased free cholesterol (FC). FC accumulation induced endoplasmic reticulum stress via IRE1A and protein kinase RNA-like ER kinase/ATF4/CCAAT-enhancer-binding protein homologous protein pathways and autophagy. TSPO deficiency activated cellular adaptive antioxidant protection; this adaptation was lost upon excessive FC accumulation. A TSPO ligand 19-Atriol blocked cholesterol binding and recapitulated many of the alterations seen in TSPO-deficient cells. These data suggest that TSPO deficiency accelerated the progression of SS. In NASH, however, loss of TSPO ameliorated liver fibrosis through down-regulation of bile acid synthesis by reducing CYP7A1 and CYP27A1 levels and increasing farnesoid X receptor expression. These studies indicate a dynamic and complex role for TSPO in the evolution of NAFLD.

INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is a chronic clinicopathological condition associated with significant lipid deposition in hepatocytes and an increased risk of liver injury (Abd El-Kader and El-Den Ashmawy, 2015; Huang et al., 2020). NAFLD encompasses a wide histological spectrum of diseases ranging from simple steatosis (SS) without inflammation or fibrosis to nonalcoholic steatohepatitis (NASH) with inflammation and eventually cirrhosis and ultimately hepatocellular carcinoma (HCC) (Brown and Kleiner, 2006; Kleiner et al., 2005). In Western countries, NAFLD has become one of the most prevalent chronic liver diseases (Benedict and Zhang, 2017). Therefore, it is of crucial importance to impede SS and NASH progression because these two stages can still be reversed to normal (Kleiner et al., 2005).

Translocator protein (TSPO; 18 kDa), a ubiquitous high-affinity cholesterol- and drug-binding protein located in the outer mitochondrial membrane (OMM), has been well-characterized by its direct or indirect involvement in numerous biological functions, including mitochondrial cholesterol transport, steroid hormone biosynthesis, cell proliferation, apoptosis, porphyrin transport, heme synthesis, and anion transport (Papadopoulos et al., 2006, 2018). In a normal human liver, TSPO expression is low (Papadopoulos et al., 2006; Savino et al., 2016) but increases in NAFLD (Hatori et al., 2015). Recent studies demonstrated serious steatosis aggregates and necroinflammatory infiltration during the progression from NASH to HCC in the higher-upgrade regions of 18F-FEDAC, a radiotracer specific for TSPO (Hatori et al., 2014; Xie et al., 2012). Therefore, TSPO has been proposed as a specific molecular imaging biomarker of NAFLD. However, the function of TSPO in the progression of NAFLD is still unknown.

Total cholesterol (TC) is present as unesterified free cholesterol (FC) and cholesteryl ester (CE). Acyl-coenzyme A: cholesterol acyltransferase (ACAT) is an intracellular enzyme that catalyzes the formation of CE.
from FC and long-chain fatty acyl-CoA (Chang et al., 1998). The ACAT family includes two members, ACAT1 and ACAT2. In the liver, ACAT1 is distributed only in Kupffer cells (Parini et al., 2004), whereas ACAT2 is expressed primarily in hepatocytes (Anderson et al., 1998). Thus, ACAT regulates the balance between FC and CE forms. Any perturbation of this balance will disrupt cholesterol homeostasis and lead to pathological conditions, from hypercholesterolemia (Daniels et al., 2009) to NAFLD (Lee et al., 2009; Tous et al., 2005). Mice fed with a high-fat diet showed FC accumulation in mouse hepatic stellate cells (HSCs), which further sensitized these cells to TGFβ-induced activation, leading to exaggerated liver fibrosis in NASH (Tomita et al., 2014). In addition, after treatment of isolated liver sinusoidal endothelial cells with acetylated LDL (AcLDL) and ACAT inhibitor 58035 (3-[decyldimethylsilyl]-N-[2-{4-methylphenyl}-1-phenylethyl] propanamide), FC but not CE levels were significantly increased in endolysosome-enhanced TLR9-mediated signaling (Teratani et al., 2017), exacerbating the TLR9/inflammasome pathway in the liver. In the HCC cell line Huh7, acute accumulation of FC induced the degradation of perilipin 2 and Rab18-dependent fusion of the endoplasmic reticulum (ER) and lipid droplets (LDs) (Makino et al., 2016), thus perturbing cholesterol metabolism. Increased hepatic FC correlated with disease progression in patients, without CE alteration (Puri et al., 2007). These results indicated that FC accumulation, but not CE, marked NAFLD progression. However, whether TSPO affects NAFLD progression through FC accumulation remains unknown.

In this study, we induced lipid accumulation in vitro by treating Huh7 cells or primary mouse hepatocytes with either AcLDL to increase TC or AcLDL+58035 to induce FC accumulation in the presence or absence of TSPO. We also treated Huh7 cells with 19-Atriol, a ligand binding at the cholesterol recognition amino acid consensus (CRAC) domain of TSPO (Midzak et al., 2011), to inhibit cholesterol binding to assess whether it can reproduce the effects exhibited after loss of TSPO function. We examined FC accumulation, LD alterations, and the TSPO-ACAT2 association. Furthermore, we investigated the effect of FC accumulation on ER stress and autophagy. We also induced in vivo NASH in wild-type and TSPO-knockout (KO) rats using the methionine-choline-deficient (MCD) diet and investigated the role of TSPO in the fibrotic liver.

RESULTS

TSPO levels correlated with the progression for NAFLD

Although TSPO was reported to be a potential indicator for NAFLD progression (Hatori et al., 2014; Xie et al., 2012), there has surprisingly been no comprehensive study of TSPO expression across the spectrum of NAFLD. To that end, we examined TSPO expression at all stages of NAFLD in the human and mouse. The human liver samples were first blind scored using the NAFLD activity score (NAS) system by a pathologist, regardless of gender. A total of 12 samples were randomly picked as representative of different liver stages by NAS grades of normal, steatosis, NASH, and cirrhosis (n = 3 for each stage) for further analysis (Table S1). TSPO immunoreactivity was low in a normal liver but elevated in SS, NASH, and cirrhotic livers (Figure 1A, black arrows). After the removal of areas of blood and vessels by ImageJ software, TSPO signal intensity was significantly higher in patients with steatosis, NASH, and cirrhosis than in controls, and this increase was proportional to the extent of liver damage.

We assessed TSPO expression in mouse liver sections from different stages of NAFLD generated in mice fed with a diet rich in fructose, palmitate, and cholesterol (Wang et al., 2016). The steatosis group (n = 12) was generated after 20 weeks of feeding with a fructose-palmitate-cholesterol diet (FPC) supplemented with 0.05% cholesterol, and the NASH group (n = 9) was generated after 22 weeks of feeding with a FPC diet supplemented with 1.2% cholesterol. The control group (n = 6) was generated after 20 weeks of feeding with a chow diet. TSPO immunoreactivity was low in a normal liver but elevated in SS, NASH, and cirrhotic livers (Figure 1B). After the removal of areas of blood and vessels by ImageJ software, TSPO signal intensity was significantly higher in patients with steatosis, NASH, and cirrhosis than in controls, and this increase was proportional to the extent of liver damage.

FC and TAG accumulation in TSPO-deficient cells after AcLDL+58035 treatment

To examine the role of TSPO in human liver cells, we generated a stable TSPO knockdown (KD) Huh7 hepatocarcinoma cell line by transfection of human TSPO shRNA plasmid or scrambled shRNA plasmid-A (Scram). TSPO was significantly downregulated in TSPO-shRNA-transfected cells compared with Scram-shRNA-transfected cells (Figure 2A). The immunofluorescence staining of TSPO and MitoTracker confirmed reduced TSPO density in mitochondria by shRNA (Figure 2B).
Using zinc finger nuclease technology, we previously generated a TSPO null mutant rat (Owen et al., 2017). Serendipitously, we observed abnormal LD accumulation in TSPO homozygous KO rats when compared with WT and heterozygous TSPO rats (Figure S1), implying a liver steatosis-like phenotype in TSPO HO KO rats. This observation prompted us to explore the possible contribution of TSPO to lipid accumulation and NAFLD. First, we demonstrated AcLDL uptake into Huh7 by visualizing the acetylated low-density lipoprotein, DiI complex (Dil-AcLDL) trafficking into the cells (Figure S2A). To assess the effect of TSPO in lipid-loaded Huh7 cells, we treated KD and Scram control Huh7 cells for 24 h with AcLDL to increase TC levels or with AcLDL +58035, the latter being an ACAT inhibitor, to block cholesterol esterification. Cell viability was measured using the MTT assay. Cell viability was significantly decreased in KD cells compared with Scram (Figure 2C). After treatment with AcLDL or AcLDL+58035, cell viability continually declined and decreased more in KD than Scram, suggesting cholesterol-lipid accumulation resulted in cell death and the presence of TSPO was essential for the maintenance of cell viability.

**Figure 1. TSPO is an indicator of the progression of NAFLD**

(A) Immunohistochemistry staining showing TSPO levels in human liver paraffin sections (n = 3). The brown color indicates a positive TSPO signal (black arrow, left panel). After the removal of areas of blood and vessels by ImageJ software, quantification showed the TSPO positive signal in each field in normal, steatosis, NASH, and cirrhosis liver (right panel). Scale, 200μm.

(B) Immunofluorescence staining showing TSPO immunoreactivity signal in control (chow diet), steatosis, and NASH mouse models. The upper panels are low magnification, and the lower panels are high magnification of the selected dotted areas. Red colors indicate positive TSPO signal (white arrow). TSPO signals were quantified in control, steatosis, and NASH models. Scale, 40μm.

(C) qPCR data showing Tspo/Gapdh relative mRNA expression in mouse liver of control, steatosis, and NASH (n = 3). Data are represented as mean ± SD, *p < 0.05, **p < 0.01 by one-way ANOVA.
Figure 2. Total cholesterol or free cholesterol and TAG accumulation in TSPO-deficient cells

(A) Immunoblotting data showing Huh7 TSPO knock down (KD) cells. β-actin is a loading control.

(B) Colocalization of TSPO (green) and MitoTracker (Mito; red) under confocal microscopy. Scale, 10μm.

(C) MTT assay for Scram and KD cells treated with DMSO, AcLDL, or AcLDL+58035 for 24 h.

(D) Determination of TC, FC, and CE content in Scram and TSPO KD Huh7 after treatment with DMSO, AcLDL, and AcLDL+58035 for 24 h.

(E) Determination of TC, FC, and CE content in WT and TSPO KO primary mouse hepatocytes after treatment with DMSO, AcLDL, and AcLDL+58035 for 24 h.

(F) Determination of TAG content in Scram and KD cells after treatment with DMSO, AcLDL, and AcLDL+58035 for 24 h.

(G) Determination of TC, FC, and CE after treatment with DMSO, AcLDL, and AcLDL+19-Atriol for 24 h in Huh7.

(H) MTT assay for Huh7 cells treated with DMSO, AcLDL, and AcLDL+19-Atriol for 24 h.

(I) Measurement of TC in WT and TSPO KO mouse liver by MALDI IMS. Upper: coregistration of MS image with the optical image showing morphological features. The green indicates TC perfusion throughout the liver tissue in the hepatic lobules and around vasculature; the red indicates the distribution of heme molecule from blood cells revealing vasculature. Lower: intensity plots showing cholesterol distribution in the WT and TSPO KO liver. Scale, 5 mm.

(J) Measurement of TAG (50:2) content in the WT and TSPO KO mouse liver by MALDI. Upper: the yellow indicates TAG tissue distribution and the blue shows absence of TAG from respective tissue compartments (blood vessels or biliary ducts). The TAG signal is illustrated as a color gradient from dark blue which represents absence of TAG to yellow which shows strong TAG signal. Lower: intensity plots showing TAG distribution in WT and TSPO KO liver. Scale, 5 mm. Data are represented as mean ± SD, *p < 0.05, **p < 0.01, ***P < 0.001 by one-way ANOVA.
Next, we measured TC, FC, and CE after AcLDL or AcLDL+58035 treatment in Scram and KD cells. The results showed that AcLDL treatment slightly increased TC levels in Scram and KD cells (Figure 2D). However, there was a significant accumulation of FC in KD cells compared with Scram after AcLDL treatment. Surprisingly, TC and FC levels in KD were reduced after treatment with AcLDL+58035 compared with AcLDL (Figure 2D). Considering that cell viability decreased significantly after AcLDL+58035 treatment (Figure 2C), it is likely that excessive FC accumulation caused by 58035 led to cell death. In addition, CE levels did not change in AcLDL+58035 between Scram and KD cells. Meanwhile, we used the same treatments for 24 h on isolated hepatocytes from WT and TSPO global KO mice, previously generated in our laboratory (Fan et al., 2020). We found the treatment of hepatocytes with AcLDL or AcLDL+58035 resulted in significant increase in FC in TSPO KO cells compared with WT (Figure 2E); CE levels did not change with any treatment between WT and KO.

In addition, we isolated human hepatocytes from humanized liver-chimeric mice (Tateno et al., 2015; Yamasaki et al., 2020). After silencing TSPO using human Tspo siRNA (Figure S2B), we examined TC, FC, and CE levels after treatment with DMSO, AcLDL, and AcLDL+58035. The results obtained showed that FC is significantly elevated after silencing TSPO compared with WT cells after AcLDL+58035 (Figure S2C).

Next, we measured triacylglycerol (TAG) levels in KD and Scram cells after AcLDL or AcLDL+58035 treatment. The results showed that TAG was significantly elevated in KD cells versus Scram (Figure 2F). AcLDL or AcLDL+58035 treatment steadily and significantly promoted TAG accumulation in Scram and KD cells, with TAG levels increasing more in KD than in Scram, suggesting that the loss of TSPO enhances TAG accumulation when treated with AcLDL or AcLDL+58035.

To examine whether inhibition of cholesterol binding to TSPO was involved in the observed changes, we treated Huh7 cells with AcLDL or AcLDL+19-Atriol. We previously showed 19-Atriol is a drug ligand inhibiting FC binding at the TSPO CRAC domain (Chung et al., 2013; Midzak et al., 2011). The results showed that TC and FC levels significantly increased with AcLDL+19-Atriol treatment (Figure 2G). Given that FC accumulated after 19-Atriol treatment, it may contribute to reduce cell viability (Figure 2H). Taken together, these results demonstrate that loss of TSPO or inhibition of cholesterol binding to TSPO leads to TC, FC, and TAG accumulation, all hallmarks of hepatic steatosis.

To further examine lipid alteration in vivo after loss of TSPO, we performed matrix-assisted laser desorption/ionization imaging mass spectrometry (MALDI IMS) to assess the levels of cholesterol, TAG, and fatty acids in WT and KO mouse livers. Cholesterol was detected as [cholesterol-H2O + H]+. As seen, cholesterol (green) is evenly distributed through WT and KO livers, while the density is greater in the KO liver (Figure 2I upper). The vessels (red) were revealed by the distribution of heme molecules from blood cells. The intensity plots showed higher levels of cholesterol distribution in the TSPO KO liver compared with WT (Figure 2I lower). TAG was observed both as Na+ and K+ cations, with similar distributions for both. Because of the similarity between ions indicative of TAG (50:2, 52:2, 52:3, 52:4; Figure S3A), we chose TAG (50:2; yellow) for analysis (Figure 2J upper). The intensity plots indicate that TAG (50:2) levels were slightly elevated in the KO liver compared with the WT liver (Figure 2J lower). In addition, neither TAGs nor cholesterol was found in the bile ducts or blood vessels (Figure S3B). Furthermore, some free fatty acids, including palmitoleic/sapienic, linoleic/linolenicidic, oleic/elaidic/vaccenic, eicosapentaenoic, arachidonic, and docosahexaenoic acids were substantially higher in KO livers compared with WT livers (Figure S3C). These observations corroborate the results of cholesterol and TAG elevation in hepatocytes resulting from the loss of TSPO.

Loss of TSPO inhibited ACAT2 expression in mitochondrial-associated ER membranes (MAMs) in a manner independent of TC accumulation

Because FC accumulated in the absence of TSPO, we next determined whether there is an increase in cholesteryl ester hydrolase (CEH), which transforms CE to FC, or a decrease in ACAT2, which transforms FC to CE in TSPO-deficient cells. We detected CEH and ACAT2 levels in Scram and KD cells or WT and KO primary mouse hepatocytes, following the same treatment with AcLDL or AcLDL+58035 for 24 h. In Scram and KD cells, CEH did not change after treatment with DMSO, AcLDL, or AcLDL+58035 (Figure 3A). However, ACAT2 levels were significantly reduced in the absence of TSPO upon AcLDL or AcLDL+58035 treatment compared with their Scram controls (Figure 3B). This was confirmed by confocal imaging microscopy (Figure 3C). In mouse hepatocytes, CEH expression gradually increased with AcLDL or AcLDL+58035 treatment, more so in KO than WT cells (Figure 3D), while ACAT2 expression was downregulated in KO.
compared with WT, independent of AcLDL or AcLDL+58035 treatment, as shown by immunoblot or immu-
nofluorescence staining (Figures 3E and 3F), respectively. These results indicate that the loss of TSPO in-
hibited ACAT2 expression in a manner independent of cholesterol accumulation.

Mitochondria are juxtaposed with the ER, forming MAMs (Vance, 2014). This interorganelle interaction is
closely associated with cell stress and/or mitochondrial functions (Rizzuto et al., 1998; Zhou et al., 2020).
To address whether TSPO, located at the OMM, and ACAT2, residing in the ER membrane, interact
directly, we cotransfected a plasmid containing TSPO-Myc and a plasmid containing ACAT2-Turbo-GFP

Figure 3. Loss of TSPO inhibited ACAT2 independent of cholesterol accumulation and TSPO-ACAT2 interacted in
MAMs

(A) CEH immunoblots from DMSO-, AcLDL-, and AcLDL+58035-treated Scram and TSPO KD Huh7 cells. The numbers
under the lanes represent the CEH/GAPDH.

(B) ACAT2 immunoblot from DMSO-, AcLDL-, and AcLDL+58035-treated Scram and TSPO KD Huh7 cells. The bar graph is
the fold change of ACAT2/GAPDH.

(C) Immunofluorescence staining of ACAT2 (green) in DMSO-, AcLDL-, and AcLDL+58035-treated Scram and TSPO KD
Huh7 cells. Scale, 10 μm.

(D) CEH immunoblot from DMSO-, AcLDL-, and AcLDL+58035-treated WT and TSPO KO primary mouse hepatocytes.
The numbers under the lanes represent the CEH/GAPDH.

(E) ACAT2 immunoblot from DMSO-, AcLDL-, and AcLDL+58035-treated WT, TSPO KO primary mouse hepatocytes. The
bar graph is the fold change of ACAT2/GAPDH.

(F) Immunofluorescence staining of ACAT2 (green) in DMSO-, AcLDL-, and AcLDL+58035-treated WT and TSPO KO
primary mouse hepatocytes Scale, 10μm.

(G) Coimmunoprecipitation of ACAT2-Turbo-GFP and TSPO-Myc and immunoblot with Anti-GFP or Anti-C-Myc in Huh7
cells.

(H) PLA of ACAT2 and TSPO interactions (red spot) in Huh7 cells. Scale, 10 μm. Data are represented as mean ± SD,
*p < 0.05, **p < 0.01, ***p < 0.001 by Student’s t-test.

compared with WT, independent of AcLDL or AcLDL+58035 treatment, as shown by immunoblot or immu-
nofluorescence staining (Figures 3E and 3F), respectively. These results indicate that the loss of TSPO in-
hibited ACAT2 expression in a manner independent of cholesterol accumulation.

Mitochondria are juxtaposed with the ER, forming MAMs (Vance, 2014). This interorganelle interaction is
closely associated with cell stress and/or mitochondrial functions (Rizzuto et al., 1998; Zhou et al., 2020).
To address whether TSPO, located at the OMM, and ACAT2, residing in the ER membrane, interact
directly, we cotransfected a plasmid containing TSPO-Myc and a plasmid containing ACAT2-Turbo-GFP
into Huh7 cells and performed coimmunoprecipitation (CO-IP) studies. We validated the overexpression of ACAT2 and TSPO by immunoblotting with anti-ACAT2 and c-Myc antibodies, respectively (Figures S4A and S4B). After immunoprecipitation of anti-Turbo-GFP or c-Myc antibodies from clarified cell lysates, we performed immunoblot analysis using either anti-rabbit C-Myc or Turbo-GFP antibodies. The results show a band of 18–20 kDa, the approximate size of TSPO-Myc, after immunoprecipitation with anti-Turbo-GFP or a 68-kDa ACAT2-GFP band after immunoprecipitation with anti-C-Myc antibody (Figure 3G), suggesting that TSPO interacts directly with ACAT2. To further examine whether endogenous TSPO and ACAT2 interacts, we performed proximity ligation assay (PLA) in Huh7 cells with anti-TSPO (LifeSpan, # LS-BS55-50) and anti-ACAT2 antibodies. The confocal photomicrographs clearly show that endogenous TSPO and ACAT2 interact as seen by the red fluorescence distributed around the nuclei (Figure 3H). These observations provide strong evidence for the direct interaction between TSPO and ACAT2 at the level of MAMs. D’Eletto et al. reported first that TSPO is present in the MAM fraction and its localization is strictly transglutaminase-type-2-dependent in HEK293 cells (D’Eletto et al., 2018). Herein, we confirmed TSPO presence in MAMs and identified TSPO-ACAT2 interactions in hepatocytes.

To detect whether the TSPO-ACAT2 interaction is associated with cholesterol accumulation, we treated the Huh7 cells with DMSO, AcLDL, or AcLDL+58035 and performed immunoblotting with TSPO-Myc after immunoprecipitation with Turbo-GFP. The results show no change in the intensity of TSPO-Myc (Figures S4C and S4D), suggesting that TSPO and ACAT2 interact in a cholesterol-accumulation-independent manner.

To further explore cholesterol metabolism after the loss of TSPO, we examined the transcriptional levels of Acat2 and liver X receptor α (Lxrα) and Lxrα downstream factors HMG-CoA reductase (Hmgcr) and sterol regulatory-element-binding transcription factor 1 (Srebp-1c). Acat2mRNA showed decreased trend and Lxrα levels were significantly reduced after loss of TSPO in control (DMSO), AcLDL, and AcLDL+58035 treatments. Although no significant changes were seen in Hmgcr and Srebp-1c levels, the HMGCR protein was reduced in TSPO KO in all treatments examined (Figures S4E and S4F), suggesting that there was no de novo cholesterol synthesis. It was intriguing, however, that Lxrα and Acat2 levels were both reduced in TSPO KO Huh7 compared with WT cells. This finding is in disagreement with a previous report showing that LXRα may negatively regulate ACAT2 expression (Bonamassa and Moschetta, 2013). To assess whether ACAT2 may be degraded in TSPO KO cells, ACAT2 was immunoprecipitated in extracts of mouse hepatocytes from WT and TSPO KO animals, and the precipitates were immunoblotted with an antibubiquitin antibody. The results obtained showed no changes in the ubiquitination of ACAT2 between WT and TSPO KO cells (Figure S4G), indicative of no ubiquitination-associated degradation of ACAT2 in TSPO-deficient cells.

**FC accumulation after loss of TSPO enhanced LD enlargement**

LDs are universal cellular organelles for the storage of neutral lipids, such as sterol esters and triacylglycerol synthesis (Farese and Walther, 2009). LDs protect cells from lipotoxic effects associated with various disease states, including obesity (Mardinoglu et al., 2015), type 2 diabetes (Sanjabi et al., 2015), liver steatosis (Gluchowski et al., 2017), and atherosclerosis (Plakkal Ayyappan et al., 2016). To detect LD alteration after loss of TSPO, we extracted LDs from DMSO, AcLDL or AcLDL+58035-treated Scram, and KD Huh7 cells. First, we validated the quality of the extracted LDs by immunoblotting for perilipin2 (PLIN2), the LD surface structure protein. The results showed that PLIN2 was abundantly expressed in LDs, while no GAPDH expression was found in these LDs-enriched fractions (Figure 4A, left). In contrast, PLIN2 was weakly and GAPDH highly expressed in non-LD fractions (Figure 4A, right). Next, we stained LDs with BODIPY558/568 C12 (Figure 4B upper) and quantified the frequency distribution of LDs (size and number) by ImageJ. The results show that LDs were enlarged after TC or FC accumulation caused by AcLDL or AcLDL+58035 and this enlargement was enhanced after the loss of TSPO (Figure 4B lower).

To further confirm the effect of TSPO on neutral lipid storage, we treated WT and KO primary mouse hepatocytes with DMSO, AcLDL, or AcLDL+58035 for 24 h, followed by lipid staining with Nile red (Figure 4C upper). The lipid distribution was characterized by percentage (%) area of the stained LDs normalized by the cell number. Compared with WT, the % area of LDs/cell significantly increased in KO. Upon AcLDL or AcLDL+58035 treatment, the % area of LDs/cell in KO showed significant increase compared with WT (Figure 4C lower). The maximum LD size of each group was as follows: WT DMSO, 34.4 μm; WT AcLDL 57.4 μm; WT AcLDL+58035 71 μm, while KO DMSO, 36.5 μm; KO AcLDL, 127.1 μm, and KO AcLDL+58035, 53.7 μm. These results suggest that loss of TSPO played a role in the determination of LD size and numbers through TC or FC changes.
PLIN1 and PLIN2 levels are increased in steatotic hepatocytes (Fujii et al., 2009; Straub et al., 2008) and in rodents and humans with NAFLD (Straub et al., 2008), promoting triglyceride accumulation (Imai et al., 2007). After AcLDL treatment, we found that there was a significant increase in Plin2 but not Plin1 expression in TSPO KO hepatocytes compared with WT cells (Figure 4D), suggesting the changes seen in LD morphology are due to changes in expression of structural LD proteins. Interestingly, we noticed that Lxrα levels may be positively correlated with Plin2 at the transcriptional level (Figure S4E). Expression of Ppara, responsible for fatty acid β-oxidation, and the lipogenesis genes Dgat2, Fasn, and Scd1 was not significantly changed after cholesterol accumulation (Figure 4D). Together, these results suggest that loss of TSPO augmented LD size partly through changes in genes important for LD structure, which agrees with previous studies (Makino et al., 2016).

We also investigated the effect of inhibiting Niemann-Pick type C1 (NPC1) on LDs in Scram and KD cells. NPC1 is a protein critical for late endosomes and lipid transport, and disruption of NPC1 by the inhibitor

---

**Figure 4. LDs enlargement in TSPO-deficient cells**

(A) Immunoblot validation of LDs from Scram and TSPO KD cells treated with DMSO, AcLDL, and AcLDL+58035. The left panel indicates PLIN2 expression but no GAPDH in LD-enriched fraction, the right panel indicates non-LDs fraction by weak PLIN2 but normal GAPDH expression.

(B) LDs staining with BODIPY (red color). LDs size-frequency distribution quantification by ImageJ. Scale, 50 μm.

(C) Nile red staining (red color) of WT and TSPO KO primary mouse hepatocytes treated with DMSO, AcLDL, and AcLDL+58035. Nuclei were stained with DAPI. The LDs were quantified as the % area of LDs/cell. Scale, 50 μm.

(D) qPCR data showing relative mRNA levels of Plin1, Plin2, Ppara, Dgat2, Fasn and Scd1 versus Rps18 in WT and TSPO KO primary mouse hepatocytes treated with DMSO, AcLDL, and AcLDL+58035. Data are represented as mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001 by student’s t-test.
U18666A has been shown to result in cholesterol accumulation in lysosomes. We found that LD size increased more significantly in TSPO KD cells versus Scram in response to U18666A treatment (Figure S5A). Likewise, we found LD size is larger in KD cells than Scram after treatment with MβCD (methyl-β-cyclodextrin)/cholesterol, which depletes cholesterol, followed by loading of cholesterol in the presence of 58035 (Figure S5B). However, after treatment with the fatty acid principle monounsaturated oleic acid, we did not see changes in LD size in KD compared with Scram cells (Figure S5C), suggesting the presence of different regulatory mechanisms for TSPO in cholesterol and free fatty acid accumulation.

**TSPO deficiency aggravated ER stress via excessive FC**

To determine whether loss of TSPO initiated ER stress, we examined the levels of the master regulator of ER stress GRP-78 (glucose-regulated protein 78) and ER stress markers, IRE1α (inositol requiring kinase enzyme 1 alpha), PERK (protein-kinase-RNA-like ER kinase), and ATF (activating transcription factor) in primary mouse hepatocytes after treatment. With DMSO treatment, GRP-78, PERK, ATF4, and its downstream target CCAAT-enhancer-binding protein homologous protein (CHOP) showed higher levels in KO compared with WT cells, indicating ER stress induction after loss of TSPO. After AcLDL or AcLDL+58035 treatment, GRP-78, PERK, ATF4, and CHOP continuously increased in KO compared with WT cells. GRP78 and CHOP levels were quantified in the PERK/ATF4/CHOP cascade (Figure 5A). IRE1α levels increased in KO compared with WT in DMSO. After AcLDL or AcLDL+58035 treatment, IRE1α levels decreased continuously, although they remained higher in KO than those seen in WT, suggesting dynamic regulation. ATF6, another ER-stress-signal-transduction cascade marker, did not change under these conditions (Figure S6). The CHOP levels (green) in WT and KO mouse hepatocytes were confirmed by immunostaining in these treatments (Figure 5B). Given the presence of greater amounts of FC accumulation in TSPO-deficient cells, our data suggest that ER stress induced IRE1α and the PERK/ATF4/CHOP pathway after loss of TSPO and this stress was aggravated by excessive FC accumulation mainly through the PERK/ATF4/CHOP signaling pathway.

**The adaptation of antioxidant defense protection was lost upon excessive FC accumulation in TSPO-deficient cells**

Hepatic catalase levels indicate antioxidant defense mechanisms. To assess whether TSPO plays a role in this protective system upon cholesterol accumulation, we treated primary mouse hepatocytes with DMSO, AcLDL, or AcLDL+58035. With DMSO, catalase in KO markedly increased compared with the WT, suggesting TSPO plays a protective role in the antioxidant defense process. Moreover, the catalase levels increased more in KO cells compared with WT in response to AcLDL or AcLDL+58035 (Figure 5C). The ratio of KO/WT (numbers under the lanes) after AcLDL treatment reached the highest level (4.3:1). Then, the ratio of KO/WT upon AcLDL+58035 treatment became less compared with the ratio from AcLDL treatment (3.0:1). Thioredoxin (TRX), another antioxidant marker, is playing a key role in redox signaling by removal of reactive oxygen species and nitrogen species (Matsuzawa, 2017). Here, TRX levels increased in KO compared with WT and kept a consistent ratio (1.2:1) after AcLDL+58035 treatment (Figure 5D). These results imply that TSPO deficiency aggravated ER stress via excessive FC accumulation in KO compared with WT cells, indicating ER stress induction after loss of TSPO. After AcLDL or AcLDL+58035 treatment, the ACOX1 ratio of KO/WT is 1.4:1.7:1.3, respectively (Figure 5D). These results imply that increased fatty acid β-oxidation allowed cells to consume accumulated lipid upon DMSO or AcLDL treatment in KO. However, this consumption was compromised upon excessive FC accumulation with AcLDL+58035 treatment in KO. In agreement with this, decreased fatty acid β-oxidation led to accumulation of triglycerides in cells after the loss of TSPO (Figure 2G), which may contribute to the known insulin resistance in NAFLD.

Next, we examined the levels of ACOX1 (acyl-coenzyme A oxidase 1) and PPARα, responsible for fatty acid β-oxidation in mouse hepatocytes. After AcLDL or AcLDL+58035 treatment, the ACOX1 ratio of KO/WT is 2.0:1.0:0.4 and the PPARα ratio of KO/WT is 1.4:1.7:1.3, respectively (Figure 5D). These results imply that increased fatty acid β-oxidation allowed cells to consume accumulated lipid upon DMSO or AcLDL treatment in KO. However, this consumption was compromised upon excessive FC accumulation with AcLDL+58035 treatment in KO. In agreement with this, decreased fatty acid β-oxidation led to accumulation of triglycerides in cells after the loss of TSPO (Figure 2G), which may contribute to the known insulin resistance in NAFLD.

Furthermore, we examined whether 19-Atriol treatment in Huh 7 cells could initiate ER stress or cell stress adaptation mechanisms. The results show that GRP-78, IRE1α, and CHOP levels substantially increased in response to AcLDL+19-Atriol (Figure 5E). Considering the level of FC accumulation after AcLDL+19-Atriol treatment, these results suggest that FC accumulation with 19-Atriol initiated ER stress via the IRE1α and PERK/ATF4/CHOP signaling pathways, the same pathway as loss of TSPO. Meanwhile, catalase, SOD1, and TRX levels were also elevated after AcLDL+19-Atriol treatment (Figure 5E), indicative of cell adaptation to cell stress caused by FC. Taken together, these results suggest that FC accumulation derived from either TSPO deficiency or TSPO inhibition initiated an adaptive antioxidant defense process and fatty acid β-oxidation in mouse hepatocytes. After AcLDL or AcLDL+58035 treatment, the ACOX1 ratio of KO/WT is 2.0:1.0:0.4 and the PPARα ratio of KO/WT is 1.4:1.7:1.3, respectively (Figure 5D). These results imply that increased fatty acid β-oxidation allowed cells to consume accumulated lipid upon DMSO or AcLDL treatment in KO. However, this consumption was compromised upon excessive FC accumulation with AcLDL+58035 treatment in KO. In agreement with this, decreased fatty acid β-oxidation led to accumulation of triglycerides in cells after the loss of TSPO (Figure 2G), which may contribute to the known insulin resistance in NAFLD.

Furthermore, we examined whether 19-Atriol treatment in Huh 7 cells could initiate ER stress or cell stress adaptation mechanisms. The results show that GRP-78, IRE1α, and CHOP levels substantially increased in response to AcLDL+19-Atriol (Figure 5E). Considering the level of FC accumulation after AcLDL+19-Atriol treatment, these results suggest that FC accumulation with 19-Atriol initiated ER stress via the IRE1α and PERK/ATF4/CHOP signaling pathways, the same pathway as loss of TSPO. Meanwhile, catalase, SOD1, and TRX levels were also elevated after AcLDL+19-Atriol treatment (Figure 5E), indicative of cell adaptation to cell stress caused by FC. Taken together, these results suggest that FC accumulation derived from either TSPO deficiency or TSPO inhibition initiated an adaptive antioxidant defense process and fatty acid β-oxidation in mouse hepatocytes. After AcLDL or AcLDL+58035 treatment, the ACOX1 ratio of KO/WT is 2.0:1.0:0.4 and the PPARα ratio of KO/WT is 1.4:1.7:1.3, respectively (Figure 5D). These results imply that increased fatty acid β-oxidation allowed cells to consume accumulated lipid upon DMSO or AcLDL treatment in KO. However, this consumption was compromised upon excessive FC accumulation with AcLDL+58035 treatment in KO. In agreement with this, decreased fatty acid β-oxidation led to accumulation of triglycerides in cells after the loss of TSPO (Figure 2G), which may contribute to the known insulin resistance in NAFLD.
b-oxidation. However, this adaptation was gradually lost upon excessive FC accumulation as seen with 5803 treatment, which marks the transition from SS to late SS or early NASH.

**TSPO deficiency causes autophagy**

Transmission electron microscopy (TEM) was performed on Huh7 Scram and TSPO KD cells. Compared with Scram, the mitochondrial structure in KD cells was disrupted, showing that the inner mitochondrial matrix content disappeared or showed abnormal cristae (Figure 6A red arrows). LD size was enlarged in Scram but more prominent in KD after AcLDL treatment (middle, Figures 6A and S7 red arrow), consistent with our previous observations (Figure 4B). LDs were wrapped tightly by ER in AcLDL-treated Scram cells (Figure 6A black arrowhead, upper middle), suggesting active lipid mobilization at this contact site. Cholesterol accumulation with AcLDL treatment after loss of TSPO caused more autophagosome formation (Figure 6A black arrow, lower middle panel). After treatment with AcLDL+58035, Scram LD numbers increased and

**Figure 5. Loss of TSPO enhanced ER stress and adaptation mechanism owing to FC accumulation**

(A) Immunoblot of GRP-78, PERK, ATF4, CHOP, and IRE1A in WT and TSPO KO primary mouse hepatocytes treated with DMSO, AcLDL, and AcLDL+58035. GRP-78, CHOP, and IRE1A were quantified after DMSO, AcLDL, and AcLDL+58035 treatments.

(B) CHOP immunofluorescence staining (green) in WT and TSPO KO primary mouse hepatocytes treated with DMSO, AcLDL, and AcLDL+58035. Scale, 20 μm.

(C) Immunoblot of catalase and TRX in DMSO-, AcLDL-, and AcLDL+58035-treated WT and TSPO KO primary mouse hepatocytes.

(D) Immunoblot of ACOX1 and PPARα in WT and TSPO KO primary mouse hepatocytes treated with DMSO, AcLDL, and AcLDL+58035.

(E) Immunoblot of GRP-78, IRE1A, CHOP, catalase, SOD1, and TRX in Huh7 cells treated with DMSO, AcLDL, and AcLDL+19-Atriol. The ratio in A, C, and D indicates the densitometric analysis of the tested protein versus the corresponding GAPDH. Data are represented as mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001 by student’s t-test.
sizes became larger (Figure 6A upper right). The treatment of AcLDL+58035 in TSPO KD showed more autophagolysosomes formation (double black arrows, lower right).

To determine if cholesterol accumulation affected autophagy as seen under TEM, we detected autophagy-specific markers microtubule-associated protein 1 light chain 3 (LC3) and lysosome-associated membrane protein 1 and 2 (LAMP1 and LAMP2, respectively) in Scram and KD cells and in WT and KO primary mouse hepatocytes. LC3-II was upregulated in KD cells and increased with AcLDL and AcLDL+58035 treatment compared to Scram (Figure 6B). LAMP1 did not change with DMSO or AcLDL treatment between Scram and KD but was slightly upregulated with AcLDL+58035 in KD (Figure 6B). The upregulated LC3-II and LAMP1 confirmed elevated autophagolysosome formation in TSPO KD compared with Scram under AcLDL+58035 treatment as observed under TEM (double black arrows, lower right Figure 6A). In mouse hepatocytes, LC3B-II gradually increased in TSPO KO compared with WT upon DMSO, AcLDL, and AcLDL+58035. LC3-II was quantified with GAPDH in (C). The ratio indicates the densitometric analysis of LC3-II/GAPDH, ATG12/GAPDH, and LAMP2/GAPDH. Data are represented as mean ± SD, *p < 0.05, **p < 0.01 by one-way ANOVA.

(E) Immunoblot of LC3 in Huh7 cells treated with DMSO, AcLDL, and AcLDL+19-Atriol.
plot to display the changes (Figure S8). Ingenuity Pathway Analysis was performed to identify potential canonical expression pattern (Figure 7C). The transcriptome changes between these 4 groups were analyzed as scatter differences (Figure 7B). Hierarchical clustering analysis further confirmed that each group displayed a distinct gene WT and KO rats after a chow diet or MCD, we performed RNA sequencing (RNA-seq) on samples from 4 groups: Tspo expression paralleled liver fibrosis development (Figures S9C–S9E). qPCR and immunoblot analyses validated this result may also suggest that FC accumulation derived from TSPO inhibition caused autophagy but need further investigation. Thus, we concluded that loss or inhibition of TSPO altered mitochondrial morphology and enhanced interactions between the ER and LDs. TC accumulation after loss of TSPO resulted in autophagy, and excessive FC accumulation led to more autophagolysosomes.

Moreover, we treated Huh7 cells with AcLDL+19-Atriol and found LC3-II substantially increased compared with Scram and AcLDL-treated cells (Figure 6E). Because AcLDL+19-Atriol led to FC accumulation (Figure 2G), this result may also suggest that FC accumulation derived from TSPO inhibition caused autophagy but need further investigation. Thus, we concluded that loss or inhibition of TSPO altered mitochondrial morphology and enhanced interactions between the ER and LDs. TC accumulation after loss of TSPO resulted in autophagy, and excessive FC accumulation led to more autophagolysosomes.

Loss of TSPO ameliorated liver fibrosis and inflammation in MCD-Induced NASH
To assess whether changes in TSPO expression regulated liver fibrogenesis, we fed WT and Tspo KO rats (Owen et al., 2017) an MCD diet for 2 months, which is enough to generate NASH associated with fibrosis. Serum analysis showed that the circulating cholesterol levels tended to increase, while serum alanine transaminase (ALT) was reduced in Tspo KO MCD as compared with WT MCD rats (Figure 7A). Bile acid (BA) levels were significantly reduced in Tspo KO MCD compared with WT MCD. To compare the transcriptome profiles between Tspo WT and KO rats after a chow diet or MCD, we performed RNA sequencing (RNA-seq) on samples from 4 groups: WT chow, Tspo KO chow, WT MCD, and Tspo KO MCD. Principal component analysis (PCA) highlighted the differences (Figure 7B). Hierarchical clustering analysis further confirmed that each group displayed a distinct gene expression pattern (Figure 7C). The transcriptome changes between these 4 groups were analyzed as scatter plots to display the changes (Figure 5B). Ingenuity Pathway Analysis was performed to identify potential canonical pathways, diseases and functions, and gene networks associated with RNA-seq readouts, and the results are listed in Table S2. Comparisons of NASH markers Col1a1 and Acta2 and markers for cholesterol metabolism Cyp27a1, Cyp7a1, and Fgf21 between WT chow and WT MCD and between KO chow and KO MCD were analyzed (Figures 5A and 5B). Tspo levels were increased in MCD compared with a chow diet, suggesting Tspo expression paralleled liver fibrosis development (Figures 5C–5E). qPCR and immunoblot analyses validated Tspo depletion in KO rats (Figures 7D and 7E). The inflammation markers Lgals1, Tnfα, F4/80, Tlr4, and Slc20a1 (also known as Pit1) were decreased (Figure 7D), suggesting less inflammation in KO than WT after MCD. TNFα (Tumor necrosis factor alpha) was again shown downregulated in Tspo KO MCD compared with WT MCD by immunoblot analysis (Figure 7E). Farnesoid X receptor (Fxr or Nr1h4), a negative regulator of BA formation, was significantly increased in Tspo KO versus WT with MCD (Figure 7D), suggesting less BA synthesis in Tspo KO. Increased levels of FGF21 have been shown to correlate with NAFLD progression (Su et al., 2019), which was seen in WT MCD compared to WT chow (Figure 7D). Immunoblot analysis also showed that α actin 2 (Acta2) was increased in Tspo KO versus WT with MCD. Responsible for BA synthesis, cholesterol 7 alpha-hydroxylase A1 (Cyp7a1) was downregulated in Tspo KO MCD as compared with WT MCD. However, FXR levels significantly increased in Tspo KO versus WT after MCD (Figure 7E), suggesting reduced BA production in Tspo KO rats compared to WT. Furthermore, Sirius red staining showed significantly reduced collagen fibers in Tspo KO in comparison to WT MCD rats (Figure 7F), indicating less fibrosis in KO MCD compared with WT MCD. Taken together, our results suggest that the loss of TSPO ameliorated liver fibrosis and inflammation through downregulation of BA synthesis.

DISCUSSION
Herein, we demonstrated several essential roles for TSPO in the progression of NAFLD. Loss of TSPO in hepatocytes triggers the onset of steatosis by TC, FC, and TAG accumulation. Mechanistically, TSPO physically interacts with ACAT2 at MAMs, and loss of TSPO inhibited ACAT2, resulting in FC accumulation in a manner independent of TC accumulation. Moreover, TSPO deficiency induced IRE1A and PERK/ATF4/CHOP pathways in ER stress and autophagy formation and FC accumulation aggravated these events. Meanwhile, TC and FC accumulation after the loss of TSPO led to LD enlargement. Mild TC accumulation after the loss of TSPO initially triggered a cell adaptation mechanism, but excessive FC accumulation caused the loss of this adaptive response. 19-Atriol can specifically block TSPO functions leading to FC accumulation, which phenocopies many biological events in ER stress, autophagy, and antioxidant
reaction. In the NASH model, the loss of TSPO ameliorated the liver fibrosis and inflammation by reducing BA production through upregulating FXR and downregulating CYP27A1 and CYP7A1. Collectively, our results suggest that TSPO plays an essential role in all stages of NAFLD progression. The loss of TSPO may initiate SS, but in vivo it also ameliorates liver fibrogenesis and inflammation, halting progression in NAFLD.

TSPO is ubiquitously expressed (Papadopoulos et al., 2006, 2018; Wyatt et al., 2012). In normal livers, TSPO expression is relatively low but becomes elevated upon liver injuries, such as those in response to carbon tetrachloride (CCl4) or cycloheximide injection (Hatori et al., 2014, 2015; Xie et al., 2012). In this study, we confirmed that TSPO levels were indicative of the progression of NAFLD from patients and rodent samples.

To determine TSPO levels in different cell subtypes of the liver, we isolated hepatocytes, HSCs, and Kupffer cells from rats. Tspo mRNA is mainly found in HSCs and Kupffer cells and in low levels in hepatocytes (Figure S10). However, considering hepatocytes occupy more than 70% of the liver, we specifically investigated TSPO role in the hepatocyte cell line Huh7 cell and in primary mouse hepatocytes after lipid loading to mimic NAFLD.

Under chow diet feeding, we observed lipid accumulation in the TSPO KO rat liver by LDs staining and the TSPO KO mouse liver by MALDI IMS as compared with the controls. Thus, we specifically examined the role of TSPO in hepatocytes for SS progression because there is no (or less) activation of HSCs and Kupffer cells at this stage. Given the role of TSPO in binding and transporting cholesterol into mitochondria, we expected TC accumulation in the absence of TSPO. Surprisingly, we noticed FC elevation in TSPO-deficient cells compared with the control, even in the absence of AcLDL treatment. To gain further insight into the mechanism of FC accumulation in TSPO-deficient cells, we looked at levels of the convertases, CEH, and ACAT2, which ultimately determine the levels of free and esterified cholesterol in hepatocytes (Anderson et al., 1998; Chang et al., 1998; Parini et al., 2004). The loss of TSPO suppressed ACAT2 activity independent of cholesterol accumulation, implying that TSPO deficiency can induce FC accumulation by decreasing ACAT2 conversion of FC to CE. Furthermore, we performed Co-IP and PLA and revealed that the mitochondrial TSPO directly interacts with the ER ACAT2 independent of cholesterol accumulation. These findings provide evidence that the TSPO-ACAT2 interaction in MAMs may be a potential modulator for the TC and FC homeostasis and, furthermore, should have an impact on NAFLD progression.

An inhibitor of ACAT 58035 enhances FC accumulation after AcLDL treatment by blocking FC conversion to CE. However, we did not see a continuous increase in FC in response to AcLDL+58035 compared with AcLDL treatment in Huh7. Instead, both TC and FC content decreased in TSPO KD after AcLDL+58035 treatment compared with AcLDL, which might be due to the decreased cell viability in AcLDL+58035. However, in isolated mouse hepatocytes, TC and FC continuously increased after AcLDL or AcLDL+58035 treatment, which was more striking in TSPO KO cells compared with WT, implying that mouse primary hepatocytes are less susceptible to the impairment caused by FC accumulation than the human Huh7 cell line.

The catalase antioxidant system was triggered further after AcLDL treatment in mouse TSPO KO hepatocytes compared with DMSO, suggesting that the cells adapt to maintain cellular homeostasis in some extent. However, this adaptation was lost under additional stress as seen with FC accumulation after treatment with AcLDL+58035 compared with AcLDL treatment in Huh7. An inhibitor of ACAT 58035 enhances FC accumulation after AcLDL treatment by blocking FC conversion to CE. However, we did not see a continuous increase in FC in response to AcLDL+58035 compared with AcLDL treatment in Huh7. Instead, both TC and FC content decreased in TSPO KD after AcLDL+58035 treatment compared with AcLDL, which might be due to the decreased cell viability in AcLDL+58035. However, in isolated mouse hepatocytes, TC and FC continuously increased after AcLDL or AcLDL+58035 treatment, which was more striking in TSPO KO cells compared with WT, implying that mouse primary hepatocytes are less susceptible to the impairment caused by FC accumulation than the human Huh7 cell line.

An inhibitor of ACAT 58035 enhances FC accumulation after AcLDL treatment by blocking FC conversion to CE. However, we did not see a continuous increase in FC in response to AcLDL+58035 compared with AcLDL treatment in Huh7. Instead, both TC and FC content decreased in TSPO KD after AcLDL+58035 treatment compared with AcLDL, which might be due to the decreased cell viability in AcLDL+58035. However, in isolated mouse hepatocytes, TC and FC continuously increased after AcLDL or AcLDL+58035 treatment, which was more striking in TSPO KO cells compared with WT, implying that mouse primary hepatocytes are less susceptible to the impairment caused by FC accumulation than the human Huh7 cell line.

The catalase antioxidant system was triggered further after AcLDL treatment in mouse TSPO KO hepatocytes compared with DMSO, suggesting that the cells adapt to maintain cellular homeostasis in some extent. However, this adaptation was lost under additional stress as seen with FC accumulation after treatment with AcLDL+58035 compared with AcLDL treatment in Huh7. Instead, both TC and FC content decreased in TSPO KD after AcLDL+58035 treatment compared with AcLDL, which might be due to the decreased cell viability in AcLDL+58035. However, in isolated mouse hepatocytes, TC and FC continuously increased after AcLDL or AcLDL+58035 treatment, which was more striking in TSPO KO cells compared with WT, implying that mouse primary hepatocytes are less susceptible to the impairment caused by FC accumulation than the human Huh7 cell line.
double-knockout (TSPO) and HSCs or Kupffer cells may be alternative strategies to tease out the cellular basis for TSPO effects in NASH. TSPO deficiency in HSCs and Kupffer cells, but not hepatocytes. Thus, using HSCs or cocultures of hepatocytes between SS and NASH suggests distinct roles for TSPO dependent on liver cell type and stages of NAFLD. In this model, the reduced fibrosis and inflammation after the loss of TSPO is presumably mediated by the liver. Therefore, to assess the liver phenotype in an SS animal model caused by high-fat diet feeding after the loss of TSPO function improved liver fibrogenesis by reducing BA formation. This discrepancy of the TSPO role in the liver. PARK2-mediated ubiquitination of proteins and, thus, removal of dysfunctional mitochondria, allowing for the maintenance of cellular functions (Gatliff et al., 2014). Herein, we found that lipid accumulation (cholesterol and TAG) in TSPO-deficient cells promoted autophagy. In agreement with this, Kim et al. reported that ablation of TSPO in mouse hypothalamic glial cells elicited AMPK-dependent lipophagy (autophagic degradation of intracellular LDs), breaking down LDs into free fatty acids, thereby elevating ATP in a lipid stimulus (Kim et al., 2020). Whether there is an induction of lipophagy as a consequence of lipid accumulation in TSPO-deficient cells remains to be investigated.

BA s are the final steroid metabolites of cholesterol utilization in the liver (Hanukoglu, 1992). Many BAs are highly cytotoxic (Li and Apte, 2015), and therefore, BA synthesis is under tight regulatory control. In patients with NAFLD, BA de novo synthesis has well-recognized roles in the progression of the disease (Aranha et al., 2008). In contrast, stabilization of BA levels to normal significantly improved NAFLD and type 2 diabetes mellitus (Huang et al., 2019). In our MCD NASH study, serum BA levels were suppressed in TSPO KO compared with WT rats. CYP7A1 and CYP27A1, a cholesterol 7a-hydroxylase responsible for the classic pathway and a steroid 27-hydroxylase responsible for the alternative pathway for BA synthesis, were both suppressed in the KO MCD liver compared with the WT MCD liver. The BA level was reduced by 66.7% and 73% in Cyp7a1−/− and Cyp27a1−/− mice and even more in double-knockout (Cyp7a1−/−; Cyp27a1−/−) mice (Rizzolo et al., 2019), indicative of the critical roles of these two hydroxylases in the BA metabolism. In addition, levels of FXR, a negative regulator of BA production and a BA receptor, were significantly increased in KO MCD rats compared with WT MCD. Recently, many emerging and promising therapies for NASH are designed as FXR agonists, for instance, LJN452 (Tropifexor, Novartis) (Tully et al., 2017), GS-9674 (Gilead) (Trauner et al., 2019), and Ocaliva (Intercept) (Samuretal., 2017). Ocaliva (obeticholic acid) is in phase III clinical trials for its ability to improve cholestasis liver disease and NASH by suppressing BA production in the liver, thus reducing the exposure of the liver to toxic levels of BAs (Donkers et al., 2019). Our data also showed that loss of TSPO ameliorated liver fibrosis through downregulation of BA synthesis by reducing CYP7A1 and CYP27A1 and increasing FXR expression, part of the same signaling pathway affected by Ocaliva. These data suggest that TSPO might be a potential therapeutic target for the suppression of NASH.

Despite the unequivocal evidence for the essential role of TSPO in NAFLD progression, several puzzling features remain. TSPO is a ubiquitous protein expressed in hepatocytes, HSCs, and Kupffer cells. Our study demonstrated that loss of TSPO in hepatocytes facilitated SS progression owing to FC and TAG accumulation. This model was simulated by the in vitro hepatocyte study in two aspects. First, in the SS stage, HSCs and Kupffer cells are not or less activated. Second, hepatocytes occupy most of liver parenchyma. However, it is still uncertain whether the results obtained from the hepatocyte studies depleted in TSPO can reflect the reality of SS in the liver. Therefore, to assess the liver phenotype in an SS animal model caused by high-fat diet feeding after depletion of TSPO to recapitulate the TSPO deficiency in hepatocytes is essential. In the MCD NASH model, the loss of TSPO function improved liver fibrogenesis by reducing BA formation. This discrepancy of the TSPO role between SS and NASH suggests distinct roles for TSPO dependent on liver cell type and stages of NAFLD. In the MCD NASH model, the reduced fibrosis and inflammation after the loss of TSPO is presumably mediated by TSPO deficiency in HSCs and Kupffer cells, but not hepatocytes. Thus, using HSCs or cocultures of hepatocytes and HSCs or Kupffer cells may be alternative strategies to tease out the cellular basis for TSPO effects in NASH.

Limitations of the study

Although the small cohort of patient samples used is a limitation in our study, the results obtained showed statistical significance between each stage of NAFLD. Moreover, the results obtained are in line with the observations made using labeled TSPO ligands to image TSPO expression in patients with NAFLD (Hatori et al., 2014; Xie et al., 2012). Thus, these human data provide the link between the published imaging studies and the animal models explored herein.

Resource availability

Lead contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact Vassilios Papadopoulos: Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA 90089, USA; vpapadop@usc.edu.
Materials availability
This study did not generate new unique reagents.

Data and code availability
RNA-seq data were deposited in the Gene Expression Omnibus under accession number GSE138666. All data supporting the present study are available from the corresponding author on request.

METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.

SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/10.1016/j.isci.2021.102457.

ACKNOWLEDGMENTS
We thank Dr. Cheng Ji at USC (University of Southern California) for the stimulating discussions on cell stress and autophagy, Dr. Junji Watanabe (USC) for help with confocal microscopy and MALDI coordination, Mr. Anthony Rodriguez (USC) for technical assistance with transmission electron microscopy and the Liver Histology Core of the USC Research Center for Liver Diseases for histology services (NIH grant No. P30 DK048522). We also thank Ms. Melanie Galano for critical proofreading of the manuscript. This work was supported by grants from the Canadian Institutes of Health Research (MOP125983 and PJT148659), funds from the USC School of Pharmacy and the John Stauffer Dean’s Chair in Pharmaceutical Sciences at USC, and the National Institutes of Health (R21AA027222).

AUTHOR CONTRIBUTIONS
Conceptualization, L.Y., and P.V.; Methodology, L.Y., W.J., S.C., and P.V.; Investigation, L.Y., C.L., LL., S.C., P.S., L.A., M.P., W.H., W.J., S.C., G.S., C.G., and H.T.; Writing – Original Draft, L.Y., C.L., LL., and P.V.; Writing –Review & Editing, L.Y., and P.V.; Funding Acquisition, P.V.; Resources, P.S., L.A., M.P., I.Y., S.T., G.L., and R.H.; Supervision, F.J., C.M., B.S., A.K., and P.V. All authors revised the article critically for important intellectual content. All authors have read and approved the final version of the manuscript.

DECLARATION OF INTERESTS
Dr. Yuji Ichida is an employee of PhoenixBio, Co., Ltd, Higashi-Hiroshima, Hiroshima, Japan; Dr. Cristina I. Silvescu is an employee of Bruker Daltonics, Billerica, MA 01821, USA; Dr. Jeremy J. Wolff was an employee of Bruker Daltonics, Billerica, MA 01821, USA, when this work was done.

Received: November 16, 2020
Revised: February 19, 2021
Accepted: April 19, 2021
Published: May 21, 2021

REFERENCES
Abd El-Kader, S.M., and El-Den Ashmawy, E.M. (2015). Non-alcoholic fatty liver disease: the diagnosis and management. World J. Hepatol. 7, 846–858.

Anderson, R.A., Joyce, C., Davis, M., Reagan, J.W., Clark, M., Shelness, G.S., and Rudel, L.L. (1998). Identification of a form of acyl-CoA cholesterol acyltransferase specific to liver and intestine in nonhuman primates. J. Biol. Chem. 273, 26747–26754.

Aranha, M.M., Cortez-Pinto, H., Costa, A., da Silva, J.B., Carnilo, M.E., de Moura, M.C., and Rodrigues, C.M. (2008). Bile acid levels are increased in the liver of patients with steatohepatitis. Eur. J. Gastroenterol. Hepatol. 20, 519–525.

Benedict, M., and Zhang, X. (2017). Non-alcoholic fatty liver disease: an expanded review. World J. Hepatol. 9, 715–732.

Bonamassa, B., and Moschetta, A. (2013). Atherosclerosis: lessons from LXR and the intestine. Trends Endocrinol. Metab. 24, 120–128.

Brown, G.T., and Kleiner, D.E. (2016). Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Metabolism 65, 1080–1086.

Chang, C.C., Lee, C.Y., Chang, E.T., Cruz, J.C., Levesque, M.C., and Chang, T.Y. (1998). Recombinant acyl-CoA cholesterol acyltransferase-1 (ACAT-1) purified to essential homogeneity utilizes cholesterol in mixed micelles or in vesicles in a highly cooperative manner. J. Biol. Chem. 273, 35132–35141.

Chung, J.Y., Chen, H., Midzak, A., Burnett, A.L., Papadopoulos, V., and Zirkin, B.R. (2013). Drug ligand-induced activation of translocator protein (TSPO) stimulates steroid production by aged brown Norway rat Leydig cells. Endocrinology. 154, 2156–2165.

D’Eletto, M., Rossin, F., Occhigrossi, L., Farrace, M.G., Faccenda, D., Desai, R., Marchi, S., Refolo, G., Falasca, L., Antonioli, M., et al. (2018). Transglutaminase type 2 regulates ER-mitochondria contact sites by interacting with GRP75. Cell Rep. 25, 3573–3581 e3574.

Daniels, T.F., Killinger, K.M., Michal, J.J., Wright, R.W., Jr., and Jiang, Z. (2009). Lipoproteins,
cholesterol homeostasis and cardiac health. Int. J. Biol. Sci. 5, 474–488.

Donkers, J.M., Roscam Abbing, R.L.P., and van de Graaf, S.F.J. (2019). Developments in bile salt based therapies: a critical overview. Biochem. Pharmacol. 161, 1–13.

Eccleston, H.B., Arrington, K.K., Betancourt, A.M., King, A.L., Mantena, S.K., Swan, T.M., Timoney, H.N., Noite, R.N., Nagy, T.R., Abrams, G.A., et al. (2011). Chronic exposure to a high-fat diet induces hepatic steatosis, impairs nitric oxide bioavailability, and modifies the mitochondrial proteome in mice. Antioxid. Redox Signal. 15, 447–459.

Fan, J., Campioli, E., Sottas, C., Zirkin, B., and Papadopoulos, V. (2020). Amhr2-Cre-Mediated global Tspo knockout. J. Endocr. Soc. 4, biva001–029.

Farese, R.V., Jr., and Walther, T.C. (2009). Lipid proteome in mice. Antioxid. Redox Signal. 139, 846–856, e841-846.

Kim, S., Kim, N., Park, S., Jeon, Y., Lee, J., Yoo, S.J., Lee, J.W., Moon, C., Yu, S.W., and Kim, E.K. (2020). Tarryctic Tspo inhibition induces lipophagy to regulate lipid metabolism and improve energy balance. Autophagy 16, 1200–1220.

Kleiner, D.E., Brunt, E.M., Van Natta, M., Bending, C., Contos, M.J., Cummings, O.W., Ferrell, L.D., Liu, Y.C., Torbenson, M.S., Unalp-Aranda, A., et al. (2005). Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313–1321.

Lee, L., Alloosh, M., Saxena, R., Van Altilne, W., Watkins, B.A., Klaunig, J.E., Sturek, M., and Chalasani, N. (2009). Nutritional model of steatohepatitis and metabolic syndrome in the Ossabaw miniature swine. Hepatology 50, 56–67.

Li, T., and Apte, U. (2015). Bile acid metabolism and signaling in cholestasis, inflammation, and cancer. Adv. Cancer Res. 74, 263–302.

Makino, A., Hullin-Matsuura, F., Murate, M., Abe, M., Tomishige, N., Fukuda, M., Yamashita, S., Fujimoto, T., Vidal, H., Lagarde, M., et al. (2016). Acute accumulation of free cholesterol induces the degradation of perilipin 2 and Rab28-dependent fusion of ER and lipid droplets in cultured human hepatocytes. Mol. Biol. Cell 27, 3293–3304.

Mardingolou, A., Heiker, J.T., Gartner, D., Bjornson, E., Schon, M.R., Flehmig, G., Kloting, N., Krohn, K., Fasshauer, M., Stumvoll, M., et al. (2015). Extensive weight loss reveals distinct gene expression changes in human subcutaneous and visceral adipose tissue. Sci. Rep. 5, 14841.

Matsuzawa, A. (2017). Thioredoxin and redox signaling: roles of the thioredoxin system in control of cell fate. Arch. Biochem. Biophys. 617, 101–105.

Mediza, A., Akula, N., Lecanu, L., and Papadopoulos, V. (2011). Novel androstenetriol interacts with the mitochondrial translocator protein and controls steroidogenesis. J. Biol. Chem. 286, 9875–9887.

Miele, L., Greico, A., Armuzzi, A., Candelli, M., Forgione, A., Gasbarrini, A., and Gasbarrini, G. (2003). Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by 13C-octanoate breath test. Am. J. Gastroenterol. 98, 2335–2336.

Mooreno-Fernandez, M.E., Giles, D.A., Stankiewicz, T.E., Sheridan, R., Karns, R., Cappelletti, M., Lampe, K., Mukherjee, R., Sina, C., Sallesse, A., et al. (2018). Peroxisomal beta-oxidation regulates whole body metabolism, inflammatory vigor, and pathogenesis of nonalcoholic fatty liver disease. JCI Insight 3, e93626.

Owen, D.R., Fan, J., Campioli, E., Venugopal, S., Mediza, A., Daly, E., Harlay, A., Issop, L., Libri, V., Kalogiannopoulos, D., et al. (2017). Tspo mutations in rats and a human polymorphism impair the rate of steroid synthesis. Biochem. J. 474, 3985–3999.

Papadopoulos, V., Baraldi, M., Guirala, T.R., Kostyakova, T.B., Lascape, J.J., Lindemann, P., Norenberg, M.D., Nutt, D., Weizman, A., Zhang, M.R., et al. (2006). Translocator protein (18KDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol. Sci. 27, 402–409.

Papadopoulos, V., Fan, J., and Zirkin, B. (2018). Translocator protein (18 Kda) an update on its function in steroidogenesis. J. Neuroendocrinol. 30, e12500.

Papadopoulos, V., Baraldi, M., Guirala, T.R., Kostyakova, T.B., Lascape, J.J., Lindemann, P., Norenberg, M.D., Nutt, D., Weizman, A., Zhang, M.R., et al. (2006). Translocator protein (18KDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol. Sci. 27, 402–409.

Plakkal Ayappan, J., Paul, A., and Guo, Y.H. (2016). Lipid droplet-associated proteins in atherosclerosis (Review). Mol. Med. Rep. 13, 4527–4534.

Puri, P., Baillie, R.A., West, M.M., Mirshahi, F., Choudhury, J., Cheung, O., Sargeant, C., Contos, M.J., and Sanyal, A.J. (2007). A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 46, 1081–1091.

Rizzolo, D., Buckley, K., Kong, Z., Lian, H., Stein, M., Brinker, A., Goedken, M., Buckley, B., and Guo, G.L. (2019). Bile acid homeostasis in a cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase double knockout mouse model. Hepatology 70, 389–402.

Rizzuto, R., Pinton, P., Carrington, W., Fay, F.S., Fogarty, K.E., Lifshitz, L.M., Tuft, R.A., and Pozzan, T. (1998). Close contacts with the endoplasmic reticulum as determinants of mitochondrial Ca2+ responses. Science 280, 1763–1766.

Samur, S., Klebanoff, M., Banken, R., Pratt, D.S., Chapman, R., Ollendorf, D.A., Loox, A.M., Corey, K., Hür, C., and Chhatwal, J. (2017). Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis. Hepatology 65, 920–928.

Sanjabi, B., Dastly, M., Ozcan, B., Akbarkhanzadeh, V., Rahimi, M., Vinciguerra, M., van Rooij, F., Al-Lahham, S., Sheedizador, F., van...
Satapati, S., Sunny, N.E., Kucejova, B., Fu, X., He, T.T., Mendez-Lucas, A., Shelton, J.M., Perales, J.C., Browning, J.D., and Burgess, S.C. (2012). Elevated TCA cycle function in the pathology of diet-induced hepatic insulin resistance and fatty liver. J. Lipid Res. 53, 1080–1092.

Savin, S., Denora, N., Iacobazzi, R.M., Porcelli, L., Azzariti, A., Natile, G., and Margiotta, N. (2016). Synthesis, characterization, and cytotoxicity of the first oxaliplatin Pt(IV) derivative having a TSPO ligand in the axial position. Int. J. Mol. Sci. 17, 1010.

Straub, B.K., Stoeffel, P., Heid, H., Zimbelmann, R., and Schirmacher, P. (2008). Differential pattern of lipid droplet-associated proteins and de novo perilipin expression in hepatocyte steatogenesis. Hepatology 47, 1936–1946.

Su, X., Kong, Y., and Peng, D. (2019). Fibroblast growth factor 21 in lipid metabolism and non-alcoholic fatty liver disease. Clin. Chim. Acta 498, 30–37.

Sunny, N.E., Parks, E.J., Browning, J.D., and Burgess, S.C. (2011). Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab. 14, 804–810.

Takahashi, Y., and Fukusato, T. (2014). Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J. Gastroenterol. 20, 15339–15348.

Tateno, C., Kawase, Y., Tobita, Y., Hamamura, S., Ohshita, H., Yokomichi, H., Sanada, H., Kakuni, M., Shiota, A., Kojima, Y., et al. (2015). Generation of novel chimeric mice with humanized livers by using hemizygous cDNA-upA/SCID mice. PLoS One 10, e0126145.

Teratani, T., Tomita, K., Suzuki, T., Furuhashi, H., Irie, R., Hida, S., Okada, Y., Kurihara, C., Ebihara, H., Nakamoto, N., et al. (2017). Free cholesterol accumulation in liver sinusoidal endothelial cells exacerbates acetaminophen hepatotoxicity via TLR9 signaling. J. Hepatol. 67, 780–790.

Tomita, K., Teratani, T., Suzuki, T., Shimizu, M., Sato, H., Narimatsu, K., Okada, Y., Kurihara, C., Irie, R., Yokoyama, H., et al. (2014). Free cholesterol accumulation in hepatic stellate cells: mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice. Hepatology 59, 154–169.

Tous, M., Ferre, N., Camps, J., Riu, F., and Joven, J. (2005). Feeding apolipoprotein E-knockout mice with cholesterol and fat enriched diets may be a model of non-alcoholic steatohepatitis. Mol. Cell. Biochem. 268, 53–58.

Trauner, M., Gulamhusein, A., Hameed, B., Caldwell, S., Shiffman, M.L., Lands, C., Eksteen, B., Agarwal, K., Muir, A., Rushbrook, S., et al. (2019). The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis. Hepatology 70, 789–801.

Tully, D.C., Rucker, P.V., Chianelli, D., Williams, J., Vidal, A., Alper, P.B., Mutnick, D., Bursula, B., Schmeits, J., Wu, X., et al. (2017). Discovery of tropifexor (LJN452), a highly potent non-bile acid FXR agonist for the treatment of cholestatic liver diseases and nonalcoholic steatohepatitis (NASH). J. Med. Chem. 60, 9960–9973.

Tyagi, S., Gupta, P., Saini, A.S., Kaushal, C., and Sharma, S. (2011). The peroxisome proliferator-activated receptor: a family of nuclear receptors role in various diseases. J. Adv. Pharm. Technol. Res. 2, 236–240.

Vance, J.E. (2014). MAM (mitochondria-associated membrane) in mammalian cells: lipids and beyond. Biochim. Biophys. Acta 1847, 595–609.

Wang, X., Zheng, Z., Caviglia, J.M., Corey, K.E., Herfel, T.M., Cai, B., Masia, R., Chung, R.T., Lefkowitz, J.H., Schwabe, R.F., et al. (2016). Hepatocyte TAZ/MWTR1 promotes inflammation and fibrosis in nonalcoholic steatohepatitis. Cell Metab. 24, 848–862.

Wyatt, S.K., Manning, H.C., Bai, M., Ehtesham, M., Mapara, K.Y., Thompson, R.C., and Bornhop, D.J. (2012). Preclinical molecular imaging of the translocator protein (TSPO) in a metastases model based on breast cancer xenografts propagated in the murine brain. Curr. Mol. Med. 12, 458–466.

Xie, L., Yui, J., Hatori, A., Yamasaki, T., Kumata, K., Wakizaka, H., Yoshida, Y., Fujinaga, M., Kawamura, K., and Zhang, M.R. (2012). Translocator protein (18 kDa), a potential molecular imaging biomarker for non-invasively distinguishing non-alcoholic fatty liver disease. J. Hepatol. 57, 1076–1082.

Yamasaki, C., Ishida, Y., Yanagi, A., Yoshizane, Y., Kojima, Y., Ogawa, Y., Kayegaya, Y., Iwasaki, Y., Ishida, S., Chayama, K., et al. (2020). Culture density contributes to hepatic functions of fresh human hepatocytes isolated from chimeric mice with humanized livers: novel, long-term, functional two-dimensional in vitro tool for developing new drugs. PLoS One 15, e0237809.

Zhou, Z., Torres, M., Sha, H., Halbrook, C.J., Vanden Bergh, F., Renert, R.B., Yamada, T., Wang, S., Luo, Y., Hunter, A.H., et al. (2020). Endoplasmic reticulum-associated degradation regulates mitochondrial dynamics in brown adipocytes. Science 368, 54–60.
Supplemental information

Cholesterol-binding translocator protein TSPO regulates steatosis and bile acid synthesis in nonalcoholic fatty liver disease

Yuchang Li, Liting Chen, Lu Li, Chantal Sottas, Stephanie K. Petrillo, Anthoula Lazaris, Peter Metrakos, Hangyu Wu, Yuji Ishida, Takeshi Saito, Lucy Golden-Mason, Hugo R. Rosen, Jeremy J. Wolff, Cristina I. Silvescu, Samuel Garza, Garett Cheung, Tiffany Huang, Jinjiang Fan, Martine Culty, Bangyan Stiles, Kinji Asahina, and Vassilios Papadopoulos
Figure S1
Figure S2

A

Control  Dil-AcLDL

Dil-AcLDL  DAPI

Dil-AcLDL

DAPI

B

Human Tspo siRNA

20kDa

50kDa

1.0  0.7  0.3  0.5

α-Tubulin

C

TC  FC  CE

Cholesterol (µg/mg protein)

WT  KD  WT  KD  WT  KD
Figure S3

A

WT KO
TAG(50:2) Na+
TAG(50:2) K+

WT KO
TAG(52:4) Na+
TAG(52:4) K+

WT KO
TAG(52:3) Na+
TAG(52:3) K+

WT KO
TAG(52:2) Na+
TAG(52:2) K+

B

Bile ducts

Blood vessels

WT KO WT KO WT KO WT KO

5mm

C

WT KO WT KO WT KO

Bile ducts

Blood vessels

WT KO WT KO WT KO

8mm

Figure S3
**Figure S4**

**A**

| kDa | Hub7 | ACAT2-GFP |
|-----|------|-----------|
| 75  | 50   | 37        |
| 50  | 37   | 37        |
| 37  | 37   | 37        |

GFP (68kDa)  
ACAT2 (41kDa)

**B**

| kDa | Hub7 | TSPO-Myc |
|-----|------|----------|
| 75  | 50   | 37       |
| 50  | 37   | 37       |
| 37  | 37   | 37       |

TSPO-Myc (20kDa)

**C**

| kDa | DMSO | ALDL | ALDL+58025 |
|-----|------|------|------------|
| 75  | 50   | 37   | 37         |
| 50  | 37   | 37   | 37         |
| 37  | 37   | 37   | 37         |

GFP (68kDa)

**D**

| kDa | DMSO | ALDL | ALDL+58025 |
|-----|------|------|------------|
| 75  | 50   | 37   | 37         |
| 50  | 37   | 37   | 37         |
| 37  | 37   | 37   | 37         |

TSPO-Myc (~20kDa)

**E**

| mRNA expression | Acat2 | Lxra | Hmgcr | Srebp-1c |
|-----------------|-------|------|-------|----------|
| Relative mRNA   |       |      |       |          |
| WT              |       |      |       |          |
| KO              |       |      |       |          |

**F**

| HMGCR | GAPDH |
|-------|-------|
| WT    | KO    | WT    | KO    | WT    | KO    |
| 100 kDa | 37 kDa |

| Ubiquitin conjugated proteins |
|-------------------------------|
| WT | KO |
| 37 kDa | 50 kDa |

**G**

| Protein | WT | KO |
|---------|----|----|
| ACAT2   |    |    |
| 37 kDa  |    |    |

**Legend:**
- *p < 0.05
Figure S5

A

Scram U18886  KD U18886

B

MβCD/CHOL  MβCD/CHOL +58035

C

BSA  OA

Scram

KD
Figure S6

ATF6

| WT | KO | WT | KO | WT | KO |
|----|----|----|----|----|----|

75 kDa

GAPDH

| DMSO | AcLDL | AcLDL +58635 |
|------|-------|--------------|

37 kDa
Figure S7
Figure S8

A

WT MCD
KO MCD

B

MCD-dow-Difference between 6.968 and 24.492
MCD-up-Difference between -26.025 and -1.263

C

KO-MCD specific up-regulated, 35.7%
KO MCD-specific up-regulated, 35.7%

D

KO-MCD specific down-regulated, 9.9%
MCD-down-Difference between 0.968 and 24.492
MCD-up-Difference between -26.025 and -1.263

E

Both MCD-up regulated, 82.2%
MCD-down-Difference between 0.968 and 24.492
MCD-up-Difference between -26.025 and -1.263

F

KO MCD, base pair counts (Log2)
KO chow, base pair counts (Log2)
KO-MCD, base pair counts (Log2)
WT chow, base pair counts (Log2)

G

WT chow, base pair counts (Log2)
KO-MCD, base pair counts (Log2)

H

WT chow, base pair counts (Log2)

I

Chow-WT/KO-Difference above 2 and value above 5
Chow-KO/WT-Difference above 2 and value above 5

J

MCD-WT/KO-Difference above 2 and value above 5
MCD-KO/WT-Difference above 2 and value above 5
Figure S9

(A) WT MCD
Col1a1
Acta2
Cyp27a1
Cyp7a1
Fgf21

(B) KO MCD
Col1a1
Acta2
Cyp27a1
Cyp7a1
Fgf21

WT chow, base pair counts (Log2)
KO chow, base pair counts (Log2)

WT-MCD
WT-Chow
KO-MCD
KO-Chow
Figure S10

![Bar chart showing relative mRNA expression of Tspo in different conditions: HC, KC, and HSC. The y-axis represents relative mRNA expression, ranging from 0.000 to 0.020. The x-axis labels the conditions as HC, KC, and HSC.](image-url)
Figure S11

A  TSPO conserved peptide

| Species       | Peptide Sequence     |
|---------------|----------------------|
| Mus musculus  | WRDNHGWRGGRLPE       |
| Mus Pahari    | WRDNSGRRGGSRLPE      |
| Human         | WRDNSGRRGGSRLAE      |
| Rat           | WRDNSGRRGGSRLTE      |

B

| Species       | Protein Concentration (µg) | Human heart | Rat adrenal | Mouse MA-10 |
|---------------|---------------------------|-------------|-------------|-------------|
|               | 10                        | 15          | 10          | 15          |
| Human heart   |                           |             |             |             |
| Rat adrenal   |                           |             |             |             |
| Mouse MA-10   |                           |             |             |             |

C

| Protein       | Molecular Weight (kDa) |
|---------------|------------------------|
|                | G1                     |
|                | nG1                    |
|                | G2G                    |

D

| Protein       | Molecular Weight (kDa) |
|---------------|------------------------|
|                | TSPO+DAPI              |
|                | Mitotracker+DAPI       |
|                | Merge                  |

E

| Protein       | MA-10                  |
|---------------|------------------------|
|                | G1                     |
|                | nG1                    |
|                | G2G                    |
|                | WT KO                  |

F

| Protein       | Primary mouse hepatocyte |
|---------------|--------------------------|
|                | TSPO WT                  |
|                | TSPO KO                  |

G

| Protein       | Huh7                    |
|---------------|--------------------------|
|                | MA-10 TSPO WT            |
|                | MA-10 TSPO KO            |

H

| Protein       | Huh7                    |
|---------------|--------------------------|
|                | MA-10 TSPO WT            |
|                | MA-10 TSPO KO            |
Supplemental Figure Legends

Figure S1. Related to Figure 2. The TSPO HO rats with abnormal LD accumulation displayed a steatosis phenotype. The rat liver cryosections of TSPO WT, heterozygous deletion (Het), and homozygous deletion (HO, in main text as KO) was stained with Oil Red O (red color). The results show abnormal LD (Lipid droplet) accumulation, one hallmark of steatosis, in Tspo HO rats compared to WT and Het. Scale, 200μm.

Figure S2. Related to Figure 2. Free cholesterol elevation in TSPO-deficient cells. (A) Dil-AcLDL uptake in Huh7 cells. Huh7 cells were treated with Dil-AcLDL (50μg/mL) (red color) for 24hrs, the cells were fixed in 4%PFA for 10min. After PBS washing 3 times, the cells nuclear was stained with DAPI. The images were captured under an inverted microscope. (a): Huh7 cells were treated with DMSO as control. (b): Huh7 cells were treated with Dil-AcLDL. Scale bar, 40μm. (B) TSPO was knocked out (KD) using different human Tspo siRNAs (siRNA-1, -2 and -3) in humanized mouse hepatocytes, α-Tubulin was used as the loading control. (C) Total cholesterol (TC), free cholesterol (FC) and cholesterol ester (CE) were measured in primary WT and TSPO KD (Tspo siRNA 2) humanized mouse hepatocytes. Data are represented as mean ± SD, *p<0.05, **p<0.01 by one-way ANOVA.

Figure S3. Related to Figure 2. Triglycerides and fatty acids distribution in WT and TSPO KO mouse liver. (A) Triglycerides (yellow) are observed both as Na⁺ and K⁺ cations, with similar distributions for both ions in TAG (50:2), (52:4), (52:3) and (52:2). The blue indicating blood vessels. Scale, 9mm. (B) For bile ducts, taurocholic acid was observed as an [M-H+2K]⁺ ion. For blood vessels, heme is observed as [M+] ions. In general, the TAGs were not strongly localized with either the bile ducts or blood vessels. Bile ducts: yellow. Blood vessel: blue. Scale bar, 5mm. (C) Fatty acids (yellow) were analyzed using negative ion mode with 9-AA matrix. A few of the fatty acids were observed in WT and KO tissues, with fatty acids generally being more abundant in KO tissue. Similar to the triglycerides, the fatty acids were not localized near the blood vessels (blue), but in general were fairly evenly distributed around a liver. The plots for each of the observed fatty acids showed similar trends. Specifically, elevated levels of all the observed fatty acids were observed in the KO liver compared to WT liver. a, palmitoleic/sapienic acid; b, linoleic/linolaicid acid; c, oleic/elaidic/vaccenic acid; d, eicosapentaenoic acid; e, arachidonic acid; f, docosahexaenoic acid. Scale, 8mm. Data represented as mean ± SD.

Figure S4. Related to Figure 3. TSPO directly interacts with ACAT2 in a manner independent of cholesterol accumulation. After co-transfection of TSPO-myc plasmid and ACAT2-Turbo-GFP plasmid into WT Huh7 cells, we validated the overexpression of ACAT2 with ACAT2 antibody (A) and TSPO with C-Myc antibody (B), respectively. After incubation of the anti-Turbo-GFP antibodies with clarified cell lysates, immunoblotting by Turbo-GFP (control, C) and C-Myc antibody, the results showed 18-20 kDa of TSPO band (D). The cells were treated with AcLDL or AcLDL+58035 and immunoprecipitated with GFP antibody, the results showed TSPO and ACAT2 interacted in a manner independent of cholesterol accumulation (C, D). QPCR of Acta2, Lxra, Hmgcr and Srebp-1c in primary WT and TSPO KO hepatocytes with DMSO, AcLDL and AcLDL+58035 treatment (E). Data are represented as mean ± SD, *p<0.05 by Student’s t-test. HMGCR immunoblot in WT and TSPO KO primary mouse hepatocytes with DMSO, AcLDL and AcLDL+58035 treatment (F). Immunoprecipitation with ACAT2 antibody and immunoblot with ubiquitin in WT and TSPO KO mouse hepatocytes (G).
Figure S5. Related to Figure 4. Lipid droplet frequency distribution after treatment with U18666A, MβCD/CHOL, MβCD/CHOL+58035 or oleic acid in Huh7. (A) LDs distribution (size, number) in Scram and TSPO KD Huh7 cells after U18666A treatment for 24hrs. LDs were isolated, stained with nile red, imaged (left panel) and quantified (right panel). (B) LDs distribution (size, number) in Scram and TSPO KD Huh7 cells after MβCD/CHOL or MβCD/CHOL+58035 treatment for 24hrs. The LDs were isolated, stained with nile red, imaged (left panel) and quantified (right panel). CHOL: cholesterol. (C) LDs distribution (size, number) in Scram and TSPO KD Huh7 cells after treatment with BSA or oleic acid (OA) for 24hrs. The LDs were isolated, stained with nile red, imaged (left panel) and quantified (right panel). Scale, 50µm.

Figure S6. Related to Figure 5. No change of ATF6 between WT and TSPO KO. ATF6 immunoblot in WT and TSPO KO primary mouse hepatocytes with DMSO, AcLDL and AcLDL+58035 treatment.

Figure S7. Related to Figure 6. The LD size in Scram and TSPO KD Huh7 cells after treatment with AcLDL. The Scram and TSPO KD cells were treated with DMSO and AcLDL for 24hr and then observed under TEM. Compared to Scram, the LD diameters in TSPO KD cells were enlarged with AcLDL treatment. LD, red arrow; ER, blue arrow. Scale, 500 nm.

Figure S8. Related to Figure 7. MCD diet mediated transcriptome changes in reflection in TSPO KO rats. (A) The scatterplot of RNA-seq gene expression analysis between WT chow vs. WT MCD. MCD diet mediated transcript expression data farthest away from the diagonal line were selected for further analysis. (B) The selected data points from A were overlaid on the RNA-seq transcript expression data from TSPO KO rats: KO chow vs. KO MCD. Apparently, the MCD diet-related genes were affected by TSPO KO. (C) The up-regulated MCD-mediated genes from WT are overlaid on RNA-seq transcript expression data from TSPO KO rats. Some TSPO KO specific down-regulated genes are selected (in dark), accounting for 9.9 % of the total MCD diet up-regulated genes. (D) The down-regulated MCD-mediated genes from WT were overlaid on RNA-seq transcript expression data from TSPO KO rats. Some TSPO KO specific up-regulated genes are selected (in dark), accounting of 35.7% of the total up-regulated genes by MCD diet. (E) The scatterplot of RNA-seq gene expression analysis between TSPO KO chow vs. KO MCD. The MCD diet-mediated transcript expression data farthest away from the diagonal line were selected for further comparison. (F) The MCD diet-mediated gene expression from TSPO KO rats were laid over the WT rats. Both TSPO KO vs WT shared 82.2% genes that were up-regulated and 24.9% of genes that were down-regulated. (G, H) The selected genes with over 2-fold difference between KO vs WT (chow) and KO vs WT (MCD). (I, J) The selected genes with over 5-fold difference between KO vs WT (chow) and KO vs WT (MCD).

Figure S9. Related to Figure 7. The comparisons of NASH markers (Col1a1, Acta2) and cholesterol metabolism markers (Cyp27a1, Cyp7a1, Fgf21 and Tspo) between WT chow/WT MCD and KO chow/KO MCD rats. (A) The NASH markers Col1a1, Acta2 and cholesterol metabolism markers of Cyp27a1, Cyp7a1, and Fgf21 mediated by MCD diet are up regulated in the WT MCD rats. (B) The same markers are shown in the TSPO KO rats. Remarkably, the Fgf21 was down-regulated in TSPO KO MCD but up-regulated in KO chow. (C) Tspo was up regulated after MCD diet than in Chow diet. (D) Tspo was higher in WT-Chow than in KO-Chow. (E) Tspo was higher in WT-MCD than in KO-MCD.
Figure S10. Related to Figure 2. TSPO mainly expressed in the primary HSCs. Hepatocyte (HC), Kupffer cells (KC) and Hepatic stellate cells (HSC) was isolated from rat and the real-time PCR was performed. mRNA relative expression is Tspo/Gapdh.

Figure S11. Related to Figure 1 and 7. Characterization of the generated TSPO polyclonal antibody in rabbit. (A) Comparison of conserved peptide sequence in different species. Western blots of TSPO in (B) human heart lysate, (C) rat adrenal lysate, (D) mouse tumor Leydig cell line MA-10, and (E) mouse MA-10 (G1) and two MA-10 TSPO knockout (nG1 and G2G) cell lines, and (F) in primary hepatocytes from TSPO wild type and TSPO KO mouse. GAPDH was used as an internal control. (G) Co-staining of TSPO (green) and Mitotracker (Mit) (red) in WT human Huh7 cells. (H) Co-staining of TSPO (green) and Mit (red) in mouse TSPO WT MA-10 and TSPO KO MA-10 cells. Nuclear is stained by DAPI. Scale, 20µm.
Transparent Methods

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Standard Protocol Approvals and Patient Consent
The NAFLD patient study was done in accordance with the guidelines approved by McGill University Health Centre Institutional Review Board (IRB). Prior written informed consent was obtained from all subjects who participated in the study (protocol: SDR-11-669).

Experimental Animals

TSPO KO mice were generated in our laboratory (Fan et al., 2020). Tspo mutant rats (Het and KO) were generated using CompoZr® knockout Zinc Finger Nuclease Technology to delete an 89-bp fragment flanking the exon 3/intron 3 junction in Tspo gene (Owen et al., 2017). The mice or rats were bred and maintained in accordance with protocols approved by the IACUC of the University of Southern California.

For the NAFLD model, seven-week-old male C57BL/6J mice (Jackson Labs) were allowed to acclimate housing in our facility for 2 weeks before dietary intervention. Mice were fed a diet to induce NASH with the fructose-palmitate-cholesterol diet (FPC, Tekland) incorporating 1.25% cholesterol for 20 weeks (n=12). The drinking water was supplemented with 23.1g/L of glucose and 18.9 g/L fructose (55%/45% glucose/fructose ratio). Age-matched mice maintained on chow or FPC diet incorporating 0.05% cholesterol served as normal (n=6) and steatosis (n=12), respectively.

For MCD (methionine choline deficient) diet studies, TSPO WT and KO male rats aged 12 wks old were fed either regular rat chow or an MCD diet (MP Biomedicals, #960439; n = 4) for 8 wks. The rats were divided into 4 groups (WT chow, KO chow, WT MCD and KO MCD, n=4). The body weight was recorded every week. After 2 mo, deeply anesthetized rats were decapitated and trunk blood was collected into tubes (BD Vacutainer, 367820), or into a microcontainer (BD Microtainer Blood Collection Tubes, 365965) followed by 10 min centrifugation at 1200×g. The serum was collected from BD Vacutainer for bile acid analysis, the plasma was collected from BD Microtainer Blood Collection Tubes for albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), Alkaline Phosphatase, glucose, total bilirubin, total cholesterol, and triacylglycerol measurement (Antech Diagnostics, CA, USA). Fresh liver tissue samples from WT chow, KO chow, WT MCD and KO MCD were placed into micro-Eppendorf tubes and stored in -80°C for protein and RNA analyses. The left lobe from the livers from the above 4 groups were sliced with a scalpel approximately 0.5 cm in maximal dimension and fixed in 4% phosphate-buffered paraformaldehyde for 2h.

Cell culture

Human liver Huh7 cells (originally isolated from a liver tumor from a 57-year-old Japanese male) were purchased from JCRB Cell Bank. Cells, both non-transfected and transfected (see below), were grown in DMEM (Dulbecco's modified Eagle medium) supplemented with 10% heat-inactivated fetal bovine serum (Hi-FBS) and 1% penicillin-streptomycin. Cells were kept at 37°C in a humidified incubator with an atmosphere of 5% CO2.

To observe AcLDL uptake, Huh7 cells at 80% confluence were treated with Low Density Lipoprotein from Human Plasma, Acetylated, DiI complex (DiI AcLDL) (50μg/mL) for 24 hrs.
and cells were then fixed in 4% PFA for 10 min. Cells were washed 3 times with PBS, and nuclei were stained with DAPI. The images were captured with an inverted fluorescent microscope (REVOLVE, Echo, USA). For cholesterol accumulation, stable cell lines of Scram Huh7 and TSPO KD Huh7 cells were seeded until confluence reached approximately 80% and then treated with DMSO, AcLDL (Thermo Fisher Scientific, #J65029-8+, 50 µg/mL) or AcLDL and compound 58035 (Sigma, #S9318, 10 µg/mL) for 24 hrs. For the TSPO CRAC inhibitor experiment, 80% confluence Huh7 cells were treated with DMSO, AcLDL (50 µg/mL) or AcLDL (50 µg/mL) +5-Androsten-3, 17, 19-triol (19-Atriol) (100 µM) for 24 hrs., and the cells were then collected for TC and FC measurements. For cholesterol depletion using methyl-β-cyclodextrin (MβCD), KD and Scram cells were seeded in human Lipoprotein Deficient Serum (LPDS; LP4, Sigma). After treatment for 24 hrs., cells were harvested for isolation of lipid droplets with the Lipid Droplet Isolation Kit (Cell Biolabs, Inc. MET-5011). For the accumulation of free fatty acids, KD and Scram cells were treated with either 5% bovine serum albumin (BSA; fatty acid-free, endotoxin-free; IC15240105, Sigma) or 400 µM OA (O3008, Sigma) for 24 hrs. Cells were harvested for isolation of lipid droplets with the Lipid Droplet Isolation Kit (Cell Biolabs, Inc. MET-5011). For OA treatment, KD and Scram cells were treated with either 5% bovine serum albumin (BSA; fatty acid-free, endotoxin-free) or 400 µM OA for 24 hrs.

Primary mouse hepatocytes were isolated from a 8-week-old wild type male C57BL/6 and a TSPO global knock out (KO) male mouse using a two-step collagenase perfusion protocol through the portal vein (Severgnini et al., 2012). Perfusions yielded 80% initial cell viability by trypan blue exclusion and a final 93% viability following Percoll gradient centrifugation. The hepatocytes were seeded at 1×10^6/ml in basic medium containing insulin (1 µg/ml), hydrocortisone (0.25 µM) for 4 hrs or until cells were fully attached to the collagen I (Gibco, USA) coated wells, then the medium was replaced with 10% Hi-FBS DMEM. After incubation overnight, the cells were treated as noted above for cell lines.

Primary rat hepatocytes were isolated from an 8-week-old male Sprague Dawley. The isolation is as the same as described above for mouse hepatocytes. The male rat HSCs (hepatic stellate cells) and KCs (Kupffer cells) were isolated by gradient ultracentrifugation of a non-parenchymal cell-enriched fraction following pronase-collagenase digestion of the liver by the Southern California Research Center for ALPD and Cirrhosis (Li et al., 2016; Xiong et al., 2008). Cell viability was ascertained by trypan blue dye exclusion and for both HSCs and KCs was about 95%.

Human hepatocytes were isolated from humanized liver chimeric mice (HLCM). In brief, HLCM were produced by an injection of commercially available cryopreserved primary human hepatocytes (PHH) (Lot: JFC, 1-year old, Caucasian male, BioIVT Westbury, NY) into the spleen of severe combined immunodeficiency (SCID) mice with albumin enhancer/promoter driven cDNA-urokinase type plasminogen activator (cDNA-uPA) transgene expression (Tateno et al., 2015). The use of PHH for the production of HLCM has been approved by Utilization of Human Tissue Ethical Committee of PhoenixBio Co., Ltd. (0031). After 13-27 weeks post PHH injection, HLCM with high replacement rates (>90%), estimated by blood human albumin levels which is highly correlated with histological replacement index (Sugahara et al., 2020) were subjected to human hepatocyte isolation. Human hepatocytes were isolated by a two-step collagenase perfusion method as described previously (Yamasaki et al., 2020).
See results for which cell lines or isolated cells were used in any one experiment done with the methods detailed below. The methods did not change between cell lines or isolated cells except as noted.

**METHOD DETAILS**

**Clinical Data**
This study included a total of 12 liver specimens from 12 patients undergoing liver resection for different etiologies. Following sharp resection of a small liver specimen, samples were immediately perfused with ice-cold normal saline solution. After gross examination by a pathologist, samples were released. All samples were scored by a pathologist according to the NAFLD Activity Score (NAS) (Kleiner et al., 2005): normal livers (n=3), livers with steatosis (n=3), non-alcoholic steatohepatitis (NASH) (n=3) and cirrhosis (n=3) (Table S1).

**Immunohistochemical (IHC) Staining of Human Samples**
Formalin-fixed, paraffin-embedded (FFPE) human CRCLM resected blocks were used for this study. Serial sections 4 μm thick were cut from each FFPE block, mounted on charged glass slides (Superfrost Plus; Fisher Scientific, Waltham, MA), and baked at 65°C for 1hr prior to staining. IHC staining was performed using the Ventana BenchMark LT fully automated machine (Ventana Medical System Inc. Arizona, USA) and stained for TSPO (1:2000; Monoclonal rabbit Anti-Human PBR, Abcam cat. No ab109497) using extended antigen retrieval (CC1 buffer). Antibodies see Table S5.

**Histopathological Analysis and Scoring of Human Samples**
All human patients’ slides were scanned at 40X magnification using the Aperio AT Turbo system. Images were viewed using the Aperio ImageScope ver.11.2.0.780 software program for scoring analysis and assessment of signals. The positivity was assessed with an Aperio ScanScope (Aperio Technologies Inc., Vista, CA), ImageScope software, and an optimized algorithm (positive pixel count V9, Aperio, Inc.).

**Histology Slides Preparation and Picro-Sirius Red Staining of Rat MCD Fed Samples**
PFA fixed liver tissues were dehydrated by sequentially increasing ethanol concentrations, cleared in xylene, and then embedded in paraffin wax. The liver collagen after MCD feeding was visualized with Picro-Sirius Red Stain Kit (American MasterTech, Pint Kit Item: KTPSRPT). Briefly, the paraffin slides were deparaffinized with xylene, rehydrated in gradient concentration of alcohol (100%, 95%, 70%, 50%) and rinsed with deionized H₂O. The slides were immersed in Picro-Sirius red stain solution for 1min following by a 0.5% acetic acid rinse. After dehydration in absolute alcohol. The slides were cleared in xylene and mounted with permanent mounting media. The images were captured with an inverted microscope (REVOLVE, Echo, USA). The collagen density was quantified using Image J software.

**Generation of Stable TSPO KD Cell Line in Huh7**
Huh7 cells were transfected with human PBR (TSPO) shRNA plasmid (Cat#: sc-40821-SH, Santa Cruz) or Scramble shRNA plasmid-A (Scram) (Cat#: sc-108060, Santa Cruz) using Lipofectamine 3000 Transfection Reagent (Thermo Fisher Scientific, Cat# L3000001). After 2 days of transfection, the cells were selected with puromycin (1 mg/ml) for two weeks. The cells were then
harvested and subjected to immunoblotting and confocal detection to confirm knockdown before use. The resulting cell lines were TSPO KD and Scram.

siRNA transfection
Human hepatocytes were transfected with human TSPO siRNA (Millipore Sigma, NM_000714: SASI_Hs01_00054085 for siRNA-1; SASI_Hs01_00054086 for siRNA-2 and SASI_Hs01_00054085 for siRNA-3, Millipore Sigma) and negative control siRNA (SIC001-5X1NMOL, Millipore Sigma) following the instructions of Lipofectamine™ RNAiMAX Transfection Reagent (Invitrogen, Cat# 13778150). The transfection efficiency was determined by immunoblot against rabbit TSPO antibody. After comparison, TSPO siRNA-2 was chosen for later experiments.

Matrix-assisted Laser Desorption/ionization (MALDI) Imaging Mass Spectrometry (IMS)
WT and TSPO KO mice 3 months old males were harvested, and the left liver lobe dissected and immediately placed on an aluminum boat floating on liquid nitrogen for 3-5 minutes. The frozen tissue was stored in -80°C for later use or immediately mounted onto a specimen disc using OCT as a mounting glue for cryostat sectioning (thickness 10 µm). The tissue sections were placed onto a Bruker ITO-coated slide (Bruker, Cat# # 237001). Slides were kept frozen at -80C until shipped on dry ice to Bruker Scientific LLC (Billerica, MA, USA). TC, CE, fatty acids, and triglycerides were examined in positive ion mode. The images were generated with SCiLS software.

Quantitative Real-time PCR (qPCR)
Total RNA was extracted from cells or tissues using Quick-RNA™ MiniPrep (#R1054&1055, Zymo Research, USA). Reverse-transcription was performed using a PrimeScript RT reagent kit (#RR037A, Takara, USA). qPCR was amplified with SYBR Green Real-Time PCR Master Mixes (#A25742, Thermo Fisher Scientific, USA) and performed on Real-Time PCR Instruments (CFX384, BIO-RAD, USA). The oligonucleotides used are listed in Table S3. The internal control is Gapdh or ribosomal protein S18 (Rps18). The relative mRNA levels per sample were calculated by subtracting the detection limit (40 Ct) from the cycle threshold value (Ct) of each gene in the same sample to obtain the ΔCt value. Taking the log2 of −ΔCt resulted in the relative expression value of each gene for each sample expressed in arbitrary units. Each value was normalized against that of Gapdh or Rps18. The samples were run independently in triplicate.

MTT Assay
Cell viability was assessed with the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) colorimetric assay (Roche, #11465007001). Briefly, the cells were seeded in a 96-well plate for overnight until confluence reached approximately 90%, and the cells were then treated with AcLDL or AcLDL + 58035 for 24 hrs. Next, the MTT solution (5 mg/mL) was added to each well for 4 h at 37°C. The resulting formazan crystals were dissolved in solubilization solution and incubated overnight at 37°C. The optical density (OD) at 595nm was then read with a Multimode Plate Reader VICTOR X5 (PerkinElmer, USA). Each treatment was replicated six times.

Lipid Droplet Isolation and Quantification
The LDs were isolated from cells with the Lipid Droplet Isolation Kit (Cell Biolabs, Inc. MET-5011). In the final step, 200µl LDs from the top LD-enriched fractions in the tube (containing the floating LDs) were picked up and transferred to a fresh microcentrifuge tube. For quality control,
samples of LD-enriched fractions were subjected to western blot for the detection of Perilipin-1, 2 and 3; only the samples with no detectable GAPDH were used for further study. For the LD size-frequency distribution study, the LDs were diluted 10 times with PBS and stained with BODIPY 558/568 C12 (Thermo Fisher Scientific, D3835) for 15min in the dark. LDs were then put onto slides and observed under a fluorescence microscope on the TXRED channel (REVOLVE, VWR). Twenty images in different fields were randomly captured using a 10-x objective. The size of the LD was quantified with ImageJ software (NIH, Bethesda, MD, USA).

**Nile Red Staining**

Nile red staining was used to localize and quantitate intracellular lipids. Briefly, 10,000 cells/100µl were seeded either in a Corning 96-Well Black Polystyrene Microplate (Sigma, CLS3603-48EA) or on coverslips inside a petri dish filled with phenol red-free complete medium (Gibco, USA) overnight. The cells were exposed to AcLDL or AcLDL+58035 for 24 h. For fluorescence observation, cells were washed twice with PBS and fixed with 4% (wt/vol) paraformaldehyde (PFA) for 10 min. Then the fixed cells were washed twice with PBS and quenched with 50mM glycine in PBS for 10min. Intracellular neutral lipids were stained with Nile red staining solution (1:100 dilution from 10mg Nile red/10ml DMSO) for 15 min in the dark. Cell nuclei were stained with DAPI (4’, 6-diamidino-2-phenylindole). All the staining procedures were performed at room temperature protecting the samples from light. Images were acquired with an inverted fluorescence microscope (REVOLVE, Echo, USA). LD size was quantified with ImageJ software.

**Cholesterol Quantification**

Total cholesterol and free cholesterol levels were measured with a Cholesterol Quantitation Kit (Sigma, MAK043-1KT). Briefly, 1×10^6 cells were trypsinized and washed with PBS, and 300ul of chloroform:isopropanol:IGEPAT CA-630 (7:11:0.1) was added in each 2ml microcentrifuge tube. The cells were homogenized by the TissueLyzer II (Qiagen, USA). After centrifugation, the organic phase was transferred to a new tube and dried at 50°C in a SpeedVac Concentrator (Thermo, SPD131DDA) for 30min to remove the chloroform. The dried lipids were then dissolved in Cholesterol Assay Buffer. A standard curve was prepared with cholesterol standard solution and cholesterol assay buffer. In a 96-well plate, 50 µl of samples and standards (1-5ng) were added to the reaction mixture and incubated at 37°C for 1 hr covered with aluminum foil. The absorbance was detected at 570nm with a Multimode Plate Reader VICTOR X5 (PerkinElmer, USA). Each sample was replicated four times.

**Triacylglycerol (TAG) Quantification**

Triglyceride quantification followed commercial kit instructions (#ab65336, Abcam) with modifications. Briefly, 10^6 cells were plated and harvested 24 hours after treatment. Cells were then resuspended and homogenized in 500 µl of 5% NP-40/ddH2O solution, followed by 5 minutes heat on a heater block and then cooled down to RT. Samples were centrifuged at 13,500 rpm for 5 mins, and 200 ul supernatant was transferred to a new tube for measurement. Standard was prepared following the instructions. Then, 50 ul of samples or standard were loaded to 96 well plates in duplicate, and 2 ul of ligase was added to each well for 20 mins incubation at RT. Finally, 50 ul of enzyme mix was added to each well of sample or standard, incubated for 1 hour at RT protected from light, and the absorbance read at 570 nm. The results were normalized to protein concentration.
Immunofluorescence Staining and Confocal Microscopy

The slides were baked at 65°C for 30 hrs prior to staining. After de-paraffinization with xylene, the slides were rehydrated with series gradient ethanol from 100%, 95%, 70%, 50% and rinsed with deionized H2O. 0.1% Trion X-100 was used for permeabilization and 5% donkey serum in 3% BSA/PBS was used to block non-specific background. Anti-TSPO (1:400; polyclonal rabbit, generated by the Papadopoulos laboratory, see supplemental information) was incubated with the slides at 4°C overnight. The anti-Rabbit IgG (H+L) Highly Alexa Fluor 647 antibody (Cat# A-31573, Thermo Fisher Scientific) was incubated for 30 mins. DAPI was added for nuclear staining. Images were acquired with an inverted fluorescence microscope (REVOLVE, Echo, USA).

Cells were seeded onto coverslips at 200,000 cells/ml in 12-well plate. For mitochondria staining, 100 nM MitoTracker Deep Red FM (Thermo Fisher Scientific, M22426) was added to the cells. After treatment, cells were fixed in 4% PFA for 10 mins, followed by permeabilization with 0.1% Triton X-100 for 10 mins and blocking with 5% donkey serum in 3% BSA/PBS for 30 mins. The cells were then incubated with primary antibodies against TSPO or ACAT2 (See Table S5) at 4°C overnight. After rinsing with PBS, cells were incubated with the appropriate second antibodies (See antibodies in Table S5). DAPI was added for nuclear staining. Images were captured with a ZEISS LSM 880 with Airyscan confocal microscope (Carl Zeiss, Germany) using a 63× Oil objective. Identical settings were used for Scram and KD cells.

Immunoblotting and Co-immunoprecipitation (Co-IP)

The proteins were extracted with RIPA buffer (Santa Cruz Biotechnology USA, sc-24948A) containing Protease Inhibitor Tablets (Pierce, #A32963). Protein concentration was determined by BCA Protein Assay (Pierce, #23225). 10µg protein was subjected to 4-20% SDS-PAGE. After transfer to the PVDF (polyvinylidene difluoride) membrane, proteins were blocked in 5% BSA 1 PBS containing 0.1% Tween-20 (PBST) for 30 mins. The primary antibody was incubated with the membrane at 4°C overnight. After washing by PBST, the horseradish peroxidase-conjugated secondary antibody was added and incubated for 1 hr. After washing with PBST, the protein band was visualized by Chemiluminescent substrate for quantitative chemiluminescent western blots (Radiance Plus, #AC2103, Azure) on an Azure Biosystem (Azure c600) (Primary and secondary antibodies were listed in Table S4). GAPDH antibody or β-actin antibody was used as an internal control. The protein band was quantified by densitometry using Image J software.

For the Co-IP assay, PBR Human Tagged ORF Clone (TSPO; NM_000714; RC220107, Origene) and Human Tagged ORF Clone ACAT2 (NM_005891; RG201821, Origene) was transfected into WT Huh7 cells. The protein was extracted from the transfected cells with Lysis/Equilibration Buffer, the interaction between TSPO-Myc and ACAT2-TuboGFP protein was performed according to the instructions for Capturem™ IP & Co-IP Kit (Takara, #635721).

For the ACAT2 antibody IP assay, WT and TSPO KO mouse hepatocytes were isolated as above. After 3 hrs culture, the medium was replaced with DMEM supplemented with 10% Hi-FBS and 1% penicillin-streptomycin, and the cells were cultured for 24 hrs. Then the cells were harvested, and the cell pellets lysed according to the instruction of Immunoprecipitation kit (Abcam, Cat# ab206996). The solubilized protein was immunoprecipitated with anti-rabbit ACAT2 (Cell signaling, Cat# 13294). For the immunoblot, after the protein separation by SDS-PAGE, the PVDF
membrane was probed with Ubiquitin monoclonal antibody (Ubi-1, # 13-1600, Thermo Fisher Scientific).

**Duolink Proximity Ligation Assay (PLA)**
Duolink In Situ Red Starter Kit (DUO92105) was purchased by Sigma-Aldrich. The assay was run per kit instructions. Briefly, Huh7 cells were seeded on a coverslip overnight. After 4% PFA fixation, the cells were covered with blocking solution. The cells were then incubated with anti-goat TSPO (LifeSpan, Cat# LS-B5755-50) and anti-rabbit ACAT2 (Cell signaling, Cat# 13294) overnight. The Duolink In Situ PLA probe anti-rabbit PLUS and Duolink In Situ PLA probe anti-goat Minus was incubated with cells for 1hr at 37°C. The ligation and amplification proceeded per the manufacturer’s instructions. Coverslips were mounted with Duolink In Situ Mounting Media with DAPI. The images were captured under a ZEISS LSM 880 with Airyscan confocal microscope (Carl Zeiss, Germany) using a 63× Oil objective.

**Transmission Electronic Microscopy (TEM)**
1×10^6 cells were harvested and fixed in 1/2 strength Karnovsky solution containing 2.5% glutaraldehyde (EM grade, Sigma) and 2% paraformaldehyde in PBS overnight at 4°C. The cell pellet was rinsed in 0.1M cacodylate buffer and post-fixed in 2% aqueous OsO₄/0.2M cacodylate buffer for 2 hours at 4°C, followed by rinsing several times with 0.1M cacodylate buffer. The cells were then EM-block stained with staturated uranyl acetate at 4°C overnight. After rinsing with 0.1M sodium acetate buffer, the cells were dehydrated through a gradient series of: 70% EtOH (ethanol), 15 min; 90% EtOH, 15 mins; 100% EtOH, 2×15 mins; propylene oxide (PO)/EtOH (1:1), 15 mins; PO/EtOH (2:1), 15 mins; and PO, 2×15 mins. Cells were then infiltrated with Epon resin/PO (1:1) overnight. After that, the cells were placed into Epon resin/PO resin (2:1) for 8 hrs, followed by vacuum polymerization in 100% Epon resin overnight. Cells were then embedded in fresh Epon resin at 60 °C for 24 hrs and subjected to ultra-thin sectioning (~70nm). The thin sections were transferred to 200 mesh copper grids and stained with 2% uranyl acetate for 30 mins and 2.66% lead citrate (pH 12) for 10 mins. The images were acquired under transmission electron microscopy (JEM-2100 Electron Microscope, Japan) at the Doheny Eye Institute (Los Angeles, USA).

**RNA-seq Library Preparation and Sequencing**
Libraries for RNA-Seq were prepared with Kapa Stranded mRNA. The workflow consisted of mRNA enrichment, cDNA generation, end repair to generate blunt ends, A-tailing, adaptor ligation, and PCR amplification. Different adaptors were used for multiplexing samples in one lane. The RNA sequence data was generated on an HiSeq3000 for a single-read 50bp read run. A data quality check was done on an Illumina SAV. Demultiplexing was performed with Illumina Bcl2fastq2 v 2.17 program. RNA-seq data were deposited in the Gene Expression Omnibus under accession number GSE138666 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138666).

**RNA-seq Data Analysis**
All analyses were performed in Partek® Flow® software, version 8. For alignment, unaligned sequenced reads were trimmed from both ends to a fixed-length dependent on the positional base at which the PHRED quality score fell below 20. A minimum read length filter retaining reads greater than 25 bases in length were used. Trimmed reads were aligned to the rat genome assembly, rm6 using the STAR (version 2.6.1d) aligner. A seed mismatch limit of 1 was applied. Raw read
counts were obtained by quantitating aligned reads to rn6 (Ensembl Transcripts release 96), using a modified version of the expectation-maximization algorithm. For normalization, reads with raw counts > 10 were normalized using the Upper Quartile (UQ) normalization method. An offset of 1.0 was added to all normalized read counts. Principle components analysis (PCA) was performed to assess the overall variability in the gene dataset, in which log transformation with a log base of 2 and a log cutoff of 1.0 was applied to all normalized read counts.

For differential expression analysis, normalized read counts for each gene were statistically modeled using differential gene expression algorithm (GSA) that uses the Akaike Information Criterion corrected (AICc). Comparisons were performed with KO MCD versus WT MCD, and KO CHOW versus WT CHOW, respectively. An expression filter based on the cutoff of absolute fold change > 1.2 and \( P \)-value < 0.05 was applied to select the differential expressed (DE) genes. Hierarchical cluster analysis was performed on the subset of DE genes that were normalized by standardizing the algorithm applied across genes. The analysis was run with Pearson Correlation distance measure and average linkage clustering option.

**QUANTIFICATION AND STATISTICAL ANALYSIS**

**Statistical Analysis**
Statistical analysis was performed with GraphPad Prism 8.4.3 (Graph Pad Software, USA). Data were presented as the means ± standard deviation (SD). Statistical significance of differences was determined using an independent t-test between two groups and significant differences more than two groups were evaluated by one-way ANOVA with Tukey-Kramer as post hoc test. \( p < 0.05 \) was considered statistically significant.
### Key Resources Table for this study

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Antibodies**      |        |            |
| Monoclonal rabbit Anti-Human PBR (TSPO) | Abcam | Cat# ab109497; RRID: AB_10862345 |
| Polyclonal rabbit Anti-Human FXR (NR1H4) | Abclonal | Cat# A12788; RRID: AB_2759628 |
| Monoclonal rabbit Anti-Human ACAT2 | Cell Signaling | Cat# 13294; RRID: AB_2798172 |
| Monoclonal mouse Anti-Human Cyp7a1(clone 15B9.1) | Millipore Sigma | Cat# MABD42; RRID: AB_2756360 |
| Polyclonal rabbit Anti-Human LC3B | Millipore Sigma | Cat# L7543; RRID: AB_796155 |
| Polyclonal rabbit Anti-Human CYP27A1 | Proteintech | Cat# 14739-1-AP; RRID: AB_2089276 |
| Polyclonal rabbit Anti-Mouse TSPO | ProSci Inc | In this paper |
| **Biological samples** |        |            |
| Human NAFLD samples | Research Institute of the McGill University Health Center, Montreal, Quebec, H4A 3J1, Canada. Department of Surgery, McGill University, Montreal, Quebec, H3G 1A4, Canada | In this paper |
| Healthy Human heart lysate | ProSci, Inc. CA, USA | Cat. No. 1470 |
| Healthy Rat adrenal lysate | ProSci, Inc. CA, USA | Cat. No. 1470 |
| Primary human hepatocytes | BioIVT Westbury, NY | Lot: JFC |
| Primary rat hepatic stellate cells (From Sprague Dawley) | Southern California Research Center for ALPD and Cirrhosis, Los Angeles, CA 90089, USA | https://keck.use.edu/alpd-and-cirrhosis-research-center/ |
| Chemicals, peptides, and recombinant proteins | Suppliers and Catalog Numbers |
|---------------------------------------------|-----------------------------|
| **Primary rat hepatocytes (From Sprague Dawley)** | Southern California Research Center for ALPD and Cirrhosis, Los Angeles, CA 90089, USA | https://keck.usc.edu/alpd-and-cirrhosis-research-center/ |
| **Primary ra Kupffer cells (From Sprague Dawley)** | Southern California Research Center for ALPD and Cirrhosis, Los Angeles, CA 90089, USA | https://keck.usc.edu/alpd-and-cirrhosis-research-center/ |
| **Chemicals, peptides, and recombinant proteins** | | |
| U18666A | Calbiochem | Cat# 662015 |
| Lipoprotein deficient serum from fetal calf | Kalen Biomedical, LLC | Cat# 880100-5 |
| Goat-anti-rabbit HRP | Li-Cor | Cat# 926-80011 |
| DAPI (4’, 6-diamidino-2-phenylindole) | Life technologies | Cat# P36931 |
| 5-Androsten-3,17,19-triol | Meule, Inc. CA, USA | Quotation reference I-10729 |
| TSPO peptide | ProSci Inc | CWRDNSGRRGGSRLAE |
| 58035 | Sigma Aldrich | Cat# S9318 |
| Bovine Serum Albumin (BSA), ≥98%, Fatty Acid-free, MP Biomedicals | Sigma Aldrich | Cat# IC15240105 |
| Cholesterol–methyl-β-cyclodextrin | Sigma Aldrich | Cat# C4951-30MG |
| Chloroform | Sigma Aldrich | Cat# C2432 |
| Collagenase, Type I | Sigma Aldrich | Cat# C0130 |
| Ethanol | Sigma Aldrich | Cat# EX0276-1 |
| Hydrocortisone | Sigma Aldrich | Cat# H0888 |
| IGEPAL | Sigma Aldrich | Cat# 18896 |
| Nile red | Sigma Aldrich | Cat# 19123 |
| Oleic Acid-Albumin from bovine serum | Sigma Aldrich | Cat# O3008-5ML |
| Percoll | Sigma Aldrich | Cat# P4937 |
| Tween® 20 | Sigma Aldrich | Cat# 8221840500 |
| Product Description                                                                 | Supplier            | Catalog Number  |
|-----------------------------------------------------------------------------------|---------------------|-----------------|
| BODIPY 558/568 C12                                                                | Thermo Fisher       | Cat# D3835      |
| Collagen I rat protein                                                             | Thermo Fisher       | Cat# A1048301   |
| Cocktail proteinase inhibitor                                                      | Thermo Fisher       | Cat# 78430      |
| DMEM, high glucose                                                                | Thermo Fisher       | Cat# 11965118   |
| Insulin                                                                          | Thermo Fisher       | Cat# 2585014    |
| Low Density Lipoprotein from Human Plasma, Acetylated (AcLDL)                     | Thermo Fisher       | Cat# L35354     |
| Low Density Lipoprotein from Human Plasma, Acetylated, Dil complex (Dil AcLDL)    | Thermo Fisher       | Cat# L3484-200ul|
| NP-40 (Nonidet P-40) Surfact-Amps™ Detergent Solution                             | Thermo Fisher       | Cat# PI85125    |
| Pierce™ Protein A Plus Agarose                                                    | Thermo Fisher       | Cat# 22811      |
| Puromycin Dihydrochloride                                                          | Thermo Fisher       | Cat# A1113803   |
| Dimethyl sulfoxide (DMSO)                                                          | VWR                 | Cat# 80058-040  |
| Isopropanol                                                                      | VWR                 | Cat# BDH133     |
| **Critical commercial assays**                                                     |                     |                 |
| Immunoprecipitation kit                                                           | Abcam               | Cat# ab206996   |
| Triglyceride Assay Kit - Quantification                                           | Abcam               | Cat#: ab65336   |
| Picro-Sirius Red Stain Kit                                                        | American MasterTech | Pint Kit Item: KTPSRPT |
| Matrix-assisted laser desorption/ionization (MALDI) imaging mass spectrometry (IMS)| BRUKER              | N/A             |
| Lipid Droplet Isolation Kit                                                       | Cell Biolabs, Inc.  | Cat# MET-5011   |
| Lipofectamine™ RNAiMAX Transfection Reagent                                       | Invitrogen          | Cat# 13778150   |
| HPLC                                                                              | ProSci Inc          | N/A             |
| MTT                                                                               | Sigma Aldrich       | Cat# 11465007001|
| Cholesterol Quantification kit                                                    | Sigma Aldrich       | Cat# MAK043-1KT |
| Material                                      | Supplier        | Catalogue Number |
|----------------------------------------------|-----------------|------------------|
| Duolink In Situ Red Starter Kit              | Sigma Aldrich   | DUO92105         |
| PrimeScript RT reagent kit                   | TAKARA          | RR037A           |
| SYBR Green Real-Time PCR Master              | Thermo Fisher Scientific | A25742 |
| Lipofectamine™ 3000 Transfection Reagent    | Thermo Fisher Scientific | L3000001 |
| Quick-RNA™ MiniPrep                         | Zymo Research   | R1054 & R1055    |

Deposited data

| Type                          | Source          | Accession Number |
|-------------------------------|-----------------|------------------|
| Raw and analyzed data         | This paper      | GEO: GSE127915   |

Experimental models: cell lines

| Cell Line                     | Supplier        | Catalogue Number |
|-------------------------------|-----------------|------------------|
| Huh7 cell line                | JCRB Cell Bank  | 0403             |
| MA-10 cells                   | Fan et al., 2018| In this paper    |

Experimental models: organisms/strains

| Organism/Strain               | Reference       | Journal           |
|-------------------------------|-----------------|-------------------|
| Rat Sprague Dawley: TSPO heterozygous (Het) | David R. Owen., 2017 | Biochemical Journal 474, 3985-3999. |
| Rat Sprague Dawley: TSPO homozygous (HO, in main text as KO) | David R. Owen., 2017 | Biochemical Journal 474, 3985-3999. |
| Mouse C57BL/6/J               | Wang, X, 2016   | Cell Metab 24, 848-862. |
| Mouse C57BL/6J mouse: TSPO KO | Fan, Jinjiang, 2020 | J Endocr Soc 4, bvaa001. |

Oligonucleotides

| Oligonucleotide Description | Supplier        | Catalogue Number |
|-----------------------------|-----------------|------------------|
| Human TSPO siRNA: SASI_Hs01_00054085 | Millipore Sigma | NM_000714         |
| Human TSPO siRNA: SASI_Hs01_00054086 | Millipore Sigma | NM_000714         |
| Human TSPO siRNA: SASI_Hs01_00054085 | Millipore Sigma | NM_000714         |
| Negative control siRNA      | Millipore Sigma | SIC001-5X1NMOL    |

Recombinant DNA

| Recombinant DNA Description  | Supplier        | Catalogue Number |
|------------------------------|-----------------|------------------|
| PBR shRNA Plasmid (h)        | Santa Cruz      | sc-40821-SH      |
| Control shRNA Plasmid-A      | Santa Cruz      | sc-108060        |

Software and algorithms

| Software and Algorithms      | Supplier        | Version/Details                                      |
|------------------------------|-----------------|------------------------------------------------------|
| Photoshop CS6                | Adobe           | Adobe Photoshop Version: 19.0 20170929.r.165 2017/09/29: 1138933 x64 |
| **SCiLS** | **Bruker** | [https://www.bruker.com/en/products-and-solutions/mass-spectrometry/ms-software/scils-lab.html](https://www.bruker.com/en/products-and-solutions/mass-spectrometry/ms-software/scils-lab.html) |
| --- | --- | --- |
| **Zen lite** | **Carl Zeiss Microscopy, LLC** | [https://www.zeiss.com/microscopy/us/home.html](https://www.zeiss.com/microscopy/us/home.html) |
| **GraphPad Prism 7** | **GraphPad Software** | [http://www.graphpad.com](http://www.graphpad.com) |
| **Aperio ImageScope software** | **Leica Biosystems** | [https://www.leicabiosystems.com/digital-pathology/manage/aperio-imagescope/](https://www.leicabiosystems.com/digital-pathology/manage/aperio-imagescope/) |
| **Primer-Blast** | **NCBI** | [https://www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi?LINK_LOC=BlastHome](https://www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi?LINK_LOC=BlastHome) |
| **ImageJ Software** | **NIH** | [https://imagej.nih.gov/ij/](https://imagej.nih.gov/ij/) |
| **Partek Flow** | **Partek Flow** | [https://libguides.usc.edu/healthsciences/PartekFlow](https://libguides.usc.edu/healthsciences/PartekFlow) |
| **Ingenuity Pathway Analysis 2019** | **Qiagen** | [https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis/](https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis/) |
| **Other** | | |
| **Chow Diet, 18% Calories from Fat** | **Harlan Teklad** | # 2018 |
| **MCD diet** | **MP Biomedicals** | #960439 |
| **Picro-Sirius Red Pint Stain Kit/Ea** | **American MasterTech** | Cat# KTPSRPT |
| **MitoTracker™ Deep Red FM** | **Thermo Fisher Scientific** | Cat# M22426 |
| **Pierce™ IP Lysis Buffer** | **Thermo Fisher Scientific** | Cat# 87787 |
Table S1. NAFLD activity score (NAS) for the patient liver samples. Related to main Figures 1.

| Sample | Sex  | Age | BMI  | Diabetic | Smoking | Type of Procedure | Diagnosis                  | Steatosis | Lobular Inflammation | Hepatocyte Ballooning | Fibrosis score | % Micro steatosis | % Macro steatosis | % Total steatosis | NAS  | Grading              |
|--------|------|-----|------|----------|---------|-------------------|-----------------------------|-----------|----------------------|----------------------|----------------|-----------------|-----------------|-----------------|------|---------------------|
| 1      | Female | 52  | 21   | No       | No      | Resection         | Biliary cystadenoma         | 0         | 0                    | 0                    | 1              | 0               | 0               | 0               | 2    | Normal (Low)         |
| 2      | Female | 51  | 20   | Yes     | No      | Resection         | CRCLM                       | 0         | 1                    | 0                    | 1              | 1               | 0               | 0               | 0    | Normal (Low)         |
| 3      | Male   | 67  | 20   | No       | Yes     | Resection         | CRCLM                       | 0         | 1                    | 0                    | 1              | 1               | 0               | 0               | 0    | Normal (Low)         |
| 4      | Male   | 64  | 24   | No       | No      | Resection         | CRCLM                       | 2         | 1                    | 0                    | 1              | 15              | 30              | 45              | 4    | Steatosis (NAFLD)    |
| 5      | Male   | 52  | 25   | No       | No      | Resection         | CRCLM                       | 2         | 1                    | 1                    | 1              | 10              | 40              | 50              | 3    | Steatosis (NAFLD)    |
| 6      | Female | 78  | 19.6 | No       | No      | Resection         | CRCLM                       | 0         | 1                    | 0                    | 1              | 0.5             | 0.5             | 1               | 3    | Steatosis (NAFLD)    |
| 7      | Female | 65  | 30   | Yes     | No      | Resection         | CRCLM                       | 2         | 2                    | 1                    | 1              | 10              | 30              | 40              | 5    | NASH                 |
| 8      | Male   | 67  | 20   | No       | No      | Resection         | Net carcinoid tumor          | 2         | 3                    | 2                    | 1              | 15              | 30              | 60              | 8    | NASH                 |
| 9      | Female | 72  | 25   | No       | No      | Resection         | CRCLM                       | 1         | 2                    | 1                    | 2              | 1               | 9               | 10              | 6    | NASH                 |
| 10     | Female | 65  | 25   | No       | No      | Resection         | Benign                       | 0         | 3                    | 1                    | 3              | 0               | 0               | 0               | 0    | Cirrhosis            |
| 11     | Male   | 75  | 28   | Yes     | No      | Resection         | Benign                       | 0         | 3                    | 1 or 2               | 3              | 1               | 3               | 4               | 7    | Cirrhosis            |
| 12     | Male   | 70  | 18   | No       | No      | Resection         | Small/medium Kupffer cells  | 0         | 3                    | 2                    | 3              | 0               | 0               | 0               | 0    | Cirrhosis            |

Note: BMI, body mass index; CRCLM: colorectal cancer liver metastases
Table S2. Ingenuity Pathway Analysis of the genes involved in the liver diseases and functions. Related to main Figures 7.

| Categories | Diseases or Functions Annotation | p-value | Molecules |
|------------|----------------------------------|---------|-----------|
| Liver Proliferation | Proliferation of liver cells | 0.00495 | BMP7, IFT88, LGALS1, PIK3R1, SLC20A1, SOCS3 |
| Liver Proliferation | Proliferation of hepatocytes | 0.0347 | BMP7, IFT88, SLC20A1, SOCS3 |
| Liver Proliferation | Proliferation of oval cells | 0.0892 | IFT88 |
| Liver Fibrosis, Liver Proliferation | Proliferation of hepatic stellate cells | 0.303 | LGALS1 |
| Glutathione Depletion In Liver | Conjugation of glutathione | 0.00772 | GSTA5, GSTM1 |
| Liver Damage | Histopathological change of liver | 0.0328 | DLL4 |
| Liver Damage | Liver Damage | 0.26 | ADM, DLL4, TM4SF4, TSPO |
| Liver Damage | Hepatic injury | 0.331 | ADM, TM4SF4, TSPO |
| Biliary Hyperplasia | Hyperplasia of bile duct cells | 0.00665 | IFT88 |
| Liver Cirrhosis | Cirrhosis | 0.00712 | CD180, CYP3A5, GCLM, GUCY1A1, IL12RB2, SSTR3, TSPO |
| Liver Cirrhosis | Cirrhosis of liver | 0.0794 | CD180, CYP3A5, GCLM, IL12RB2 |
| Liver Cirrhosis | Compensated cirrhosis | 0.0831 | CYP3A5 |
| Liver Cirrhosis | Primary biliary cirrhosis | 0.145 | CD180, IL12RB2 |
| Liver Fibrosis | Fibrosis of liver portal space | 0.0133 | IFT88 |
| Liver Fibrosis | Fibrosis of liver | 0.0276 | BMP7, IFT88, SIRT6, SOCS3 |
| Liver Fibrosis | Migration of hepatic stellate cells | 0.142 | LGALS1 |
| Liver Fibrosis, Liver Proliferation | Proliferation of hepatic stellate cells | 0.303 | LGALS1 |
| Liver Inflammation/Hepatitis | Chronic inflammation of liver | 0.0133 | SIRT6 |
| Liver Inflammation/Hepatitis | Infection by Hepatitis C virus genotype 1 | 0.0831 | CYP3A5 |
| Liver Inflammation/Hepatitis | Experimental hepatitis | 0.119 | SOCS3 |
| Liver Inflammation/Hepatitis | Inflammation of liver | 0.192 | CYP3A5, IL12RB2, SIRT6, SOCS3, TSPO |
| Liver Inflammation/Hepatitis | Infection by hepatitis B virus | 0.422 | CYP3A5 |
| Hepatocellular carcinoma, Liver Hyperplasia/Hyperproliferation | Metastasis of hepatocellular carcinoma | 0.0198 | PIK3R1 |
| Liver Hyperplasia/Hyperproliferation | Early stage liver cancer | 0.0263 | SIRT6 |
| Hepatocellular carcinoma, Liver Hyperplasia/Hyperproliferation | Development of hepatocellular carcinoma | 0.0363 | MGMT, PIK3R1, SOCS3 |
| Liver Hyperplasia/Hyperproliferation | Relapsed hepatosplenic T-cell lymphoma | 0.0393 | POLE |
| Liver Hyperplasia/Hyperproliferation | Refractory hepatosplenic T-cell lymphoma | 0.0393 | POLE |
| Liver Hyperplasia/Hyperproliferation | Resectable liver cholangiocarcinoma | 0.0393 | POLE |
| Liver Hyperplasia/Hyperproliferation | Advanced liver tumor | 0.0792 | POLE, SSTR3 |
| Liver Hyperplasia/Hyperproliferation | Unresectable liver cholangiocarcinoma | 0.0831 | POLE |
| Liver Hyperplasia/Hyperproliferation | Hyperplasia of liver | 0.107 | IFT88 |
| Hepatocellular carcinoma, Liver Hyperplasia/Hyperproliferation | Hepatocellular carcinoma | 0.133 | ADCY2, AOX1, BMP7, DUSP11, ETS1, ID1, MGMT, PIK3R1, POLE, SCIMP, SOCS3, SSTR3 |
| Liver Hyperplasia/Hyperproliferation | Locally advanced liver cholangiocarcinoma | 0.148 | POLE |
| Condition                              | Disease or Function                                  | p-value | Molecules                                                                 |
|----------------------------------------|------------------------------------------------------|---------|---------------------------------------------------------------------------|
| Liver Hyperplasia/Hyperproliferation    | Proliferation of liver cancer cells                  | 0.165   | SOCS3                                                                     |
| Liver Hyperplasia/Hyperproliferation    | Metastatic liver cholangiocarcinoma                  | 0.171   | POLE                                                                      |
| Hepatocellular carcinoma, Liver Hyperplasia/Hyperproliferation | Advanced hepatocellular carcinoma                     | 0.229   | SSTR3                                                                     |
| Hepatocellular carcinoma, Liver Hyperplasia/Hyperproliferation | Childhood type hepatocellular carcinoma               | 0.234   | POLE                                                                      |
| Liver Hyperplasia/Hyperproliferation    | Hepatoblastoma                                       | 0.289   | POLE                                                                      |
| Liver Hyperplasia/Hyperproliferation    | Liver tumor                                          | 0.337   | AASS, ADCY2, AMOT, AOX1, APBA2, ARHGAP32, ARHGEF7, ATXN2, BMP7, CYP3A5, DACT2, DDT4, DTX4, DUSP11, ETS1, GNAI1, GREB1L, GSTA5, GSTM1, HIST1H3G, ID1, IFT88, KCNJ5, KLF10, LSAMP, MCM4, MEX3B, MGMT, NAV2, NKIRAS1, PARP8, PHOSPHO2, PIK3R1, PLXND1, POLE, PRRL, RCSD1, REEP1, RPL37, RXRG, SCIMP, SEPHS2, SGPL1, SIRT6, SLC25A15, SLC39A4, SOCS3, SSTR3, TMEM167B, TMEM56, UBXN2A, WDR62, ZNF48, ZNHT2 |
| Liver Hyperplasia/Hyperproliferation    | Liver cancer                                         | 0.374   | AASS, ADCY2, AMOT, AOX1, APBA2, ARHGAP32, ARHGEF7, ATXN2, BMP7, CYP3A5, DACT2, DDT4, DTX4, DUSP11, ETS1, GNAI1, GREB1L, GSTA5, GSTM1, HIST1H3G, ID1, KLF10, LSAMP, MCM4, MEX3B, MGMT, NAV2, PHOSPHO2, PIK3R1, PLXND1, POLE, RCSD1, REEP1, RPL37, RXRG, SCIMP, SEPHS2, SGPL1, SIRT6, SLC39A4, SOCS3, SSTR3, TMEM167B, UBXN2A, WDR62, ZNF48, ZNHT2 |
| Liver Hyperplasia/Hyperproliferation    | Liver carcinoma                                      | 0.402   | AASS, ADCY2, AMOT, AOX1, APBA2, ARHGAP32, ARHGEF7, ATXN2, BMP7, CYP3A5, DACT2, DDT4, DTX4, DUSP11, ETS1, GNAI1, GREB1L, GSTA5, HIST1H3G, ID1, KLF10, LSAMP, MCM4, MEX3B, MGMT, NAV2, PHOSPHO2, PIK3R1, PLXND1, POLE, RCSD1, REEP1, RPL37, RXRG, SCIMP, SEPHS2, SGPL1, SLC39A4, SOCS3, SSTR3, TMEM167B, UBXN2A, WDR62, ZNF48, ZNHT2 |

**Categories**

- **Diseases or Functions**
- **Annotation**
- **p-value**
- **Molecules**
## Table S3. Primers sequences used in the study. Related to main Figures 1, 4, 7.

| SPECIES          | GENES        | FORWARD 5'                       | 3'                      | REVERSE 5'                       | 3'                      |
|------------------|--------------|----------------------------------|-------------------------|----------------------------------|-------------------------|
| Mus musculus     | Acat2        | GCGAACGCATCAGGAATGAA             | TAGCTATTGCGCAGACACC     | Dgamt2                           | CTCCAGGAGCTGGCAC        |
|                  | Dgamt2       | CATCACCCACCTGTCGTTG             | CTCCAGGAGCTGGCAC        | Fasn                              | TGGTCTCTCTCAGGAGCTCTGT |
|                  | Gapdh        | TCCGAGACCTCGAGGCTGTA            | CTGGTTCCTCTCAGGAGCTCTGT | Hmgcr                             | GGTGGTCCAGGAGACTGAA    |
|                  | LxRα         | CGACAGTCTTTTGGTACGAGGACA         |CGCTTTTGGTACGAGCTCTGT| Plin1                             | CTGGTCTCTCTCAGGAGCTCTGT |
|                  | Plin2        | GCTCTCGAGACTGAGGTTG             |TTTCCTCTGTCAGGAGCTCTGT | Ppara                             | TGGGAGAGGAGGAGGAGGAGGTC |
|                  | Rps18        | GTGGTGAGAGGCTTTTGTCCTG          |CTGGTCTCAGGAGCTCTGT    | Srebplc                           | TGGTCTCAGGAGCTCTGT    |
|                  | Sdp1         | CCCTCCGGAATGAACGAGAG            | AAAATCCCGAAGGAGGAGGTC  | Tspo                              | TAGGCTTCAGGAGCATGCTCTTCA |
| Rattus norvegicus| Gapdh        | CCATTCTTCCACCTTTGATGCT          | TGGTGTACGATCTTATCTGT   | F4/80                             | TGGGCGCTGAAAGATTGGTTT  |
|                  | Fg21         | ACCGCGCTCCAGAACAGCTCT           |TGGAGGACCTCAGGATCAAG    | Fxr                               | TGGGCTGATGCTGATGCTG    |
|                  | Lgals1       | TACACTTCACGCCTTGTG              | TGGTCGAGCTCAGTTGATG    | Rps18                             | TGGGCGCTGAAAGATTGGTTT  |
|                  | Rps18        | ATAGGCCAGGTTCTGCGCAAC           |TGGGACACACCCGACTGAC     | Slc20a1                           | TGGGAGGAGGAGGAGGAGGTC |
|                  | Tnfα         | ATGGGCTCCCTCTCACAAGTCG          |GAAAAGTGACGATCCCAAGCG   | Tspo                              | AGAGCATTATAATTGTCAGC |
|                  | Tspo         | ATGGGCTCCCTCTCACAAGTCG          |GAAAAGTGACGATCCCAAGCG   | Tspo                              | AGAGCATTATAATTGTCAGC |

## Table S4. List of antibodies used in western blotting. Related to main Figures 2-7.

| PRIMARY ANTIBODIES | SUPPLIER | REFERENCE | DILUTION |
|--------------------|----------|-----------|----------|
| GRP-78             | Abcam    | Cat# ab21685; RRID: AB_2119834 | 1:1000 |
| HMGCR              | Abcam    | Cat# ab174830; RRID: AB_2749818 | 1:1000 |
| Oxidative Stress   | Abcam    | Cat# ab179843; RRID: AB_2716714 | 1:250 |
| Defense (Catalase, |           |           |          |
| SOD1, TRX, smooth  |           |           |          |
| muscle Actin)      |           |           |          |
| PPAR alpha         | Abcam    | Cat# ab24509; RRID: AB_448110 | 1:1000 |
| FXR                | Abclonal  | Cat# A12788; RRID: AB_2759628 | 1:1000 |
| PLIN2              | Abclonal  | Cat# A6276; RRID: AB_2766817 | 1:1000 |
| PERK               | Cell signaling | Cat# 3192; RRID: AB_2095847  | 1:1000 |
| IRE1α              | Cell signaling | Cat# 3294; RRID: AB_823545   | 1:1000 |
| ACAT2              | Cell signaling | Cat# 13294; RRID: AB_2798172 | 1:1000 |
| LAMP1              | Cell signaling | Cat# 9091; RRID: AB_2687579  | 1:1000 |
| ATF-4 (D4B8)       | Cell signaling | Cat# 11815; RRID: AB_2616025 | 1:1000 |
| α-Smooth Muscle    | Cell Signaling | Cat# 14968; RRID: AB_2798667 | 1:1000 |
| Actin              | Cell Signaling | Cat# 4180; RRID: AB_1903898  | 1:1000 |
| Antibody | Supplier | Reference | Dilution |
|----------|----------|-----------|----------|
| β-ACTIN  | Cell signaling | Cat# 4970; RRID: AB_2223172 | 1:2000 |
| CHOP (D46F1) | Cell signaling | Cat# 5554; RRID: AB_10694399 | 1:1000 |
| GAPDH   | Cell signaling | Cat# 2118; RRID: AB_561053 | 1:2000 |
| MYC-Tag | Cell signaling | Cat# 2278; RRID: AB_490778 | 1:1000 |
| CYP7A1  | Millipore | Cat# MABD42; RRID: AB_2756360 | 1:1000 |
| TSPO    | ProSci Inc | Generated by Dr. Papadopoulos lab, see supplemental information | 1:1000 |
| Lamp2   | Proteintech | Cat# 10397-1-AP; RRID: AB_2134630 | 1:1000 |
| ACOX1   | Proteintech | Cat# 10957-1-AP; RRID: AB_2221670 | 1:1000 |
| TNF Alpha | Proteintech | Cat# 17590-1-AP; RRID: AB_2271853 | 1:1000 |
| CYP27A1 | Proteintech | Cat# 14739-1-AP; RRID: AB_2089276 | 1:1000 |
| α-Tubulin | Sigma-Aldrich | Cat# T9026; RRID: AB_477593 | 1:10000 |
| LC3B    | Sigma-Aldrich | Cat# L7543; RRID: AB_796155 | 1:2000 |
| CEH     | Thermo Fisher Scientific | Cat# PA5-50285; RRID: AB_2635738 | 1:1000 |
| CHOP    | Thermo Fisher Scientific | Cat# MA1-250; RRID: AB_2292611 | 1:1000 |
| TurboGFP | Thermo Fisher Scientific | Cat# PA5-22688; RRID: AB_2540616 | 1:1000 |
| Ubiquitin | Thermo Fisher Scientific | Cat# 13-1600; RRID: AB_2533002 | 1:1000 |
| ATF6    | Novus Biological | Cat# NB1-40256; RRID: AB_2058774 | 1:1000 |

**SECONDARY ANTIBODIES**

| Antibody                  | Supplier | Reference                  | Dilution |
|---------------------------|----------|----------------------------|----------|
| Anti-Mouse IgG H&L (HRP)  | Abcam    | Cat# ab6728; RRID: AB_955440 | 1:1000   |
| Anti-Rabbit HRP           | Li-Cor   | Cat# 926-80011; RRID: AB_2721264 | 1:10000  |

**Table S5. List of antibodies used in immunohistochemistry and immunofluorescence.**
Related to main Figures 1, 3 and 5.

| Antibody | Supplier | Reference | Dilution |
|----------|----------|-----------|----------|
| TSPO     | Abcam    | Cat# ab109497; RRID: AB_10862345 | 1:2000 |
| ACAT2    | Cell signaling | Cat# 13294; RRID: AB_2798172 | 1:400 |
| TSPO     | LifeSpan | Cat# LS-B5755-50; RRID: AB_10914795 | 1:400 |
| CHOP     | Thermo Fisher Scientific | Cat# MA1-250; RRID: AB_2292611 | 1:400 |
| TSPO     | ProSci Inc | Generated by Dr. Papadopoulos lab | 1:1000 |

**SECONDARY ANTIBODIES**

| Antibody                  | Supplier | Reference                  | Dilution |
|---------------------------|----------|----------------------------|----------|
| Anti-Rabbit IgG (H+L)     | Thermo Fisher Scientific | Cat# A-21206; RRID: AB_2535792 | 1:400 |
| Highly Alexa Fluor 488    | Thermo Fisher Scientific | Cat# A-31573; RRID: AB_2536183 | 1:400 |
| Anti-Rabbit IgG (H+L)     | Thermo Fisher Scientific | Cat# A-31573; RRID: AB_2536183 | 1:400 |
| Highly Alexa Fluor 647    | Thermo Fisher Scientific | Cat# A-31573; RRID: AB_2536183 | 1:400 |
| Dilutions | Serum before purification (OD450) | Immunodepleted (flow-through) after purification (OD450) | Purified Antibody at 1.0 mg/ml (OD450) |
|-----------|----------------------------------|----------------------------------------------------------|----------------------------------------|
| 1:1,000   | 2.225                            | 0.349                                                    | 2.856                                  |
| 1:5,000   | 0.706                            | 0.111                                                    | 1.857                                  |
| 1:25,000  | 0.22                             | Not tested                                               | 0.694                                  |
| 1:125,000 | 0.092                            | Not tested                                               | 0.22                                   |
| 1:625,000 | 0.063                            | Not tested                                               | 0.105                                  |

Abbreviations: ELISA, enzyme-linked immunosorbent assay
Generation and Characterization of TSPO Polyclonal Antibody

To date, there is no commercial TSPO antibody available for the protein detection in across human, mouse, and/or rat species. Therefore, we attempted to generate a TSPO antibody applicable to human, mouse, and rat. After comparison of all the peptide sequences from manufacturers and the literature (Hatori et al., 2012; Ji et al., 2008), we picked the peptide sequence of WRDNSGRRGGSRLAE (Fig. S11A) for the synthesis and performed immunogen administration into rabbits (ProSci. Inc. CA. USA). The immunoaffinity purification was performed through a chromatography column prepared by cross-linking of the synthesized TSPO peptide (CWRDNSGRRGGSRLAE) with cysteine to a CNBr-activated Sepharose 4B gel. A direct ELISA was conducted with the serum, immunodepleted serum (or “flow-through”), and the purified antibody to check the efficiency of the purification product. These three fractions were initially brought to 1.0mg/ml and then diluted as given (Table S6), and the optical density (OD) readings taken as shown. The gradient dilution of the purified anti-TSPO antibody suggested an immune response to the antigen.

Next, we examined the antibody in tissue or cells from different species. Using this anti-rabbit TSPO antibody in immunoblots, we could detect TSPO as a 36kDa band in human heart lysate (Cat. No.: 1401, ProSci, Inc. CA, USA) (Fig. S11B), an 18kDa band in rat adrenal lysate (Cat. No. 1470, ProSci, Inc. CA, USA) (Fig. S11C) and an 18kDa band in MA-10 mouse tumor Leydig cells (Fig. S11D). With the cell lysate from mouse MA-10 and TSPO KO MA-10 cells (Fan et al., 2018), there is an 18kDa band in wild type MA-10 but no expression in TSPO KO MA-10 cells, further confirmation of the knockout of TSPO mediated by CRISPR/CAS9 in MA-10 cells (Fig. S11E) and the specificity of the antibody. Using primary hepatocytes from a male C57BL/6 wild type and a male TSPO KO mouse, after probing with TSPO antibody, results showed TSPO expression in wild type but no expression in KO hepatocytes (Fig. S11F), indicative of TSPO recognition by the generated TSPO antibody in mouse hepatocytes.

Because TSPO is a resident protein in outer mitochondrial membrane, we examined TSPO distribution in Huh7 cells under confocal laser-scanning microscopy. The results showed that TSPO was localized mainly in the mitochondrial membrane, evidenced by co-staining with MitoTracker (Fig. S11G), a mitochondrial maker. In MA-10 cells, we observed TSPO located in the mitochondrial membrane but not detected in TSPO KO MA-10 cells (Fan et al., 2018; Fig. S11H). These observations confirmed that the TSPO antibody we generated is applicable to the detection of TSPO in human, mouse, and rat. This TSPO antibody was used for immunofluorescence staining (Fig. 1B, 2B and Fig. S11 G, H) and immunoblot (Fig. 7E) in our present study.
Supplemental References
Hatori, A., Yui, J., Yamasaki, T., Xie, L., Kumata, K., Fujinaga, M., Yoshida, Y., Ogawa, M., Nengaki, N., Kawamura, K., et al. (2012). PET imaging of lung inflammation with [18F]FEDAC, a radioligand for translocator protein (18 kDa). PLoS One 7, e45065.
Ji, B., Maeda, J., Sawada, M., Ono, M., Okauchi, T., Inaji, M., Zhang, M.R., Suzuki, K., Ando, K., Staufenbiel, M., et al. (2008). Imaging of Peripheral Benzodiazepine Receptor Expression as Biomarkers of Detrimental versus Beneficial Glial Responses in Mouse Models of Alzheimer's and Other CNS Pathologies. Journal of Neuroscience 28, 12255-12267.
Li, Y., Lua, I., French, S.W., and Asahina, K. (2016). Role of TGF-beta signaling in differentiation of mesothelial cells to vitamin A-poor hepatic stellate cells in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 310, G262-272.
Severgnini, M., Sherman, J., Sehgal, A., Jayaprakash, N.K., Aubin, J., Wang, G., Zhang, L., Peng, C.G., Yucius, K., Butler, J., et al. (2012). A rapid two-step method for isolation of functional primary mouse hepatocytes: cell characterization and asialoglycoprotein receptor based assay development. Cytotechnology 64, 187-195.
Sugahara, G., Ishida, Y., Sun, J., Tateno, C., and Saito, T. (2020). Art of Making Artificial Liver: Depicting Human Liver Biology and Diseases in Mice. Semin Liver Dis 40, 189-212.
Xiong, S., She, H., Zhang, A.S., Wang, J., Mkrtchyan, H., Dynnyk, A., Gordeuk, V.R., French, S.W., Enns, C.A., and Tsukamoto, H. (2008). Hepatic macrophage iron aggravates experimental alcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 295, G512-521.